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Abstract
Pulmonary hypertension (PH) encompasses a syndrome of diseases that are characterized by 
elevated pulmonary artery pressure and pulmonary vascular remodeling and that frequently lead to 
right ventricular (RV) failure and death. Several types of PH exhibit sexually dimorphic features in 
disease penetrance, presentation, and progression. Most sexually dimorphic features in PH have 
been described in pulmonary arterial hypertension (PAH), a devastating and progressive 
pulmonary vasculopathy with a 3-year survival rate <60%. While patient registries show that 
women are more susceptible to development of PAH, female PAH patients display better RV 
function and increased survival compared to their male counterparts, a phenomenon referred to as 
the “estrogen paradox” or “estrogen puzzle” of PAH. Recent advances in the field have 
demonstrated that multiple sex hormones, receptors, and metabolites play a role in the estrogen 
puzzle and that the effects of hormone signaling may be time and compartment specific. While the 
underlying physiological mechanisms are complex, unraveling the estrogen puzzle may reveal 
novel therapeutic strategies to treat and reverse the effects of PAH/PH. In this article, we (i) review 
PH classification and pathophysiology; (ii) discuss sex/gender differences observed in patients and 
animal models; (iii) review sex hormone synthesis and metabolism; (iv) review in detail the 
scientific literature of sex hormone signaling in PAH/PH, particularly estrogen-, testosterone-, 
progesterone-, and dehydroepiandrosterone (DHEA)-mediated effects in the pulmonary 
vasculature and RV; (v) discuss hormone-independent variables contributing to sexually dimorphic 
disease presentation; and (vi) identify knowledge gaps and pathways forward.
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Several cardiopulmonary diseases are characterized by sex and gender differences and have 
been the focus of comprehensive research efforts (145). However, few of these diseases have 
seen as much progress in understanding the biological basis of these differences as 
pulmonary hypertension (PH), a pulmonary vasculopathy resulting in elevated pulmonary 
artery (PA) pressures (376). PH is not a single disease but rather a syndrome that 
encompasses a heterogeneous group of acute and chronic diseases of different origins and 
etiologies that share the common feature of mean pulmonary artery pressure (mPAP) higher 
than 20 to 25 mmHg (377). The current PH classification guidelines differentiate five major 
groups that differ in their etiologies and phenotypes (Figure 1) (377). If left untreated, PH of 
any etiology can lead to right ventricular (RV) failure and death. The majority of sex and 
gender differences in PH have been described in pulmonary arterial hypertension (PAH; 
Group 1 PH), a disease characterized by progressive pulmonary vascular remodeling 
resulting in severely increased pulmonary vascular resistance (PVR) and a high likelihood of 
RV failure and death (326, 429, 430). Sexually dimorphic features have also been described 
in other types of PH but are typically not as prevalent or pronounced as in PAH.
Sexual dimorphism in PAH exists in disease prevalence, severity of hemodynamic 
alterations, RV adaptation, treatment responses, and, importantly, survival. In particular, 
women are more prone to develop PAH, but exhibit a more favorable hemodynamic profile, 
better RV function, a better response to treatment with endothelin receptor antagonists 
(ERAs), and better survival. Men, on the other hand, are less prone to develop PAH and are 
more likely to respond to treatment with phosphodiesterase type 5 inhibitors but are more 
likely to die from this disease. More favorable hemodynamic profiles and higher survival 
rates have also been described in women with non-PAH types of PH; however, data from 
these cohorts is less abundant than for PAH.
This article comprehensively reviews the rapidly expanding biological and epidemiological 
knowledge regarding sex and gender differences in PAH and PH. We review the role of sex 
hormones, their metabolites and their receptors, and the role of nonhormonal factors in the 
pulmonary vasculature and RV in health and disease. We discuss cell culture systems, 
animal studies, and studies in humans. Knowledge gaps will be identified, and pathways 
forward will be proposed.
We use the term “PH” when discussing PH in general and the term “PAH” when specifically 
referring to this disease. By convention, elevated PA pressure in animal models is referred to 
as “PH,” while “PAH” is reserved for the human condition. According to the definitions 
published by the Institute of Medicine and embraced by the APS Journals (279, 468), we use 
the term “sex” when biologic concepts are described, but use the term “gender” when 
cultural or behavioral influences may play a role (e.g., in human studies).
A list of commonly used abbreviations is provided in the Abbreviations and Acronyms 
Section.
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Overview of PH Classifications and Pathophysiology
PH Classification and Definitions
PH has traditionally been defined as an mPAP > 25 mmHg with a classification scheme 
divided into five groups based on the predominant underlying pathology and clinical 
phenotype (Figure 1). These groups encompass Group 1 (PAH), Group 2 (PH due to left 
heart disease), Group 3 (PH due to lung disease and/or hypoxia), Group (4 PH due to PA 
obstructions such as chronic thromboembolic pulmonary hypertension [CTEPH]), and 
Group 5 (PH due to unclear or multifactorial mechanisms) (377). A detailed discussion of all 
five PH groups is beyond the scope of this article; the most up-to-date classification from the 
Proceedings of the 6th World Symposium on Pulmonary Hypertension in Nice is presented 
by Simonneau et al. (377).
Most recently, the hemodynamic definition of PH was changed to an mPAP cut-off of >20 
mmHg (377), two standard deviations above the upper limit of normal for the pulmonary 
circulation, although this remains controversial. Regardless of the threshold used for mPAP, 
the various PH phenotypes can also be classified based on the localization of the pathology 
in the pulmonary vascular compartment. Precapillary PH is characterized by (i) an elevated 
mPAP, (ii) a pulmonary arterial wedge pressure (PAWP) ≤ 15 mmHg, and (iii) a PVR ≥ 3 
Wood units. Precapillary PH occurs in Groups 1, 2, 3, and in some cases of Group 5 PH 
(377). Postcapillary PH, on the other hand, is characterized by an elevation of both mPAP (to 
>20 or 25 mmHg) and PAWP (≥ 15 mmHg). This may occur in isolation (without an 
elevation in PVR to >3 Wood units) or combined with precapillary PH such that mPAP, 
PAWP, and PVR are increased. Both isolated and combined postcapillary PH occur in Group 
2 PH and in some forms of Group 5 PH.
Pathophysiology of PAH and PH
The pathophysiology of PAH and PH has been reviewed in detail elsewhere (166, 326). An 
overview is provided in Figure 2. Briefly, PH occurs as a consequence of lesions in the 
arterial, capillary, or venous compartment of the pulmonary vasculature. In certain subtypes 
and associated conditions (e.g., pulmonary veno-occlusive disease (PVOD), drug- and toxin- 
and connective tissue disease-associated PAH, and CTEPH), a spectrum of lesions may 
occur that span more than one compartment. PH can also occur in a fairly normal pulmonary 
vasculature as a consequence of venous congestion due to left heart disease or increased 
pulmonary blood flow in the setting of hypervolemia or hyperdynamic states.
A tremendous amount of progress has been made in our understanding of PAH pathobiology 
(166, 326). Over the past several decades, discoveries that endothelial dysfunction and 
vascular remodeling occur in PAH from dysregulation of nitric oxide (NO), endothelin-1 
(ET-1), and prostacyclin pathways informed drug development and led to the approval of 
numerous pulmonary vasodilators (169). We now understand PAH to be an even more 
complex and systemic disease. Numerous cells in and around the vascular compartment, 
such as endothelial cells (ECs), smooth muscle cells (SMCs), adventitial fibroblasts, and 
inflammatory cells contribute to disease pathogenesis and are influenced by the immune and 
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hematopoietic systems as well as abnormalities in cellular energetics and metabolism. The 
current paradigm is that PAH occurs as a consequence of a single or repetitive pulmonary 
vascular injury mediated by increased pulmonary blood flow, shear stress, inflammatory 
processes, excessive vasoconstrictor stimuli, and/or EC damage. While not all individuals 
with a pulmonary vascular injury develop PAH, disease development is more likely to occur 
in the setting of genetic predisposition (e.g., mutations in bone morphogenetic protein 
receptor 2 [BMPR2]), previous vascular injury (e.g., premature birth and environmental 
exposures), and/or coexposures (e.g., hormonal and metabolic abnormalities, and substance 
abuse in HIV infection) (166, 291). Epigenetic changes may further modify the disease 
course; these multiple potential “hits” to the pulmonary vasculature are being targeted for 
potential intervention. Deep phenotyping efforts are also underway to understand common 
molecular mechanisms that may underpin and influence the severity of various forms of PH 
across all five PH groups and provide targets for precision-based medicine (152).
Right Ventricular (RV) Adaptation in PH
RV failure is an important cause of morbidity and mortality in PAH as well as Group 2 and 3 
PH from highly prevalent chronic heart and lung diseases. An estimated 70 million 
individuals in the United States may have right heart dysfunction (171, 239, 274, 282, 292, 
334, 434), yet there are no well-established biologic or clinical determinants of RV structure 
and function and no approved treatments for right heart failure. Unlike the left ventricle 
(LV), the thin-walled, compliant RV has difficulty accommodating increases in resistance 
such that even incremental increases or fluctuations in afterload over time may lead to RV 
sequelae (448, 449). There is, however, great variability in the clinical trajectory of patients, 
and they often present at later stages of disease, when RV dysfunction has already occurred. 
While RV failure is the proximate cause of death in PAH, mechanisms of RV adaptation 
(and maladaptation) have garnered much interest but remain understudied (212).
Current knowledge of the pathophysiology of RV failure has been discussed in detail 
elsewhere (346, 447, 449) and is beyond the scope of this article. A brief overview is 
presented here and in Figure 2. Initially, as RV afterload increases during PH development, 
the RV employs compensatory mechanisms that include structural changes, neurohormonal 
activation, and increased contractility (346, 449). At the cellular level, these changes are 
accompanied by increased angiogenesis, changes in mitochondrial function and substrate 
utilization, increased production of reactive oxygen species, changes in myosin isoform 
expression, and changes in sarcomere organization and structure (346). It is thought that 
these changes allow for a state of adaptive (or compensated) RV hypertrophy, characterized 
by a cardiac output that is still sufficient to meet the metabolic demands of the body (448, 
449). However, with ongoing increases in RV afterload, the RV’s compensatory mechanisms 
will eventually be exhausted and cause a transition to a maladaptive (or decompensated) 
form of RV hypertrophy (448,449). Consequently, RV failure with decreased cardiac output 
and decreased oxygen delivery occurs. At a cellular and molecular level, maladaptive RV 
hypertrophy purportedly is characterized by ischemia, impaired or insufficient angiogenesis, 
inflammation, oxidative stress, metabolic dysfunction, and impaired calcium handling, all 
associated with myocardial fibrosis and cell death (34, 447, 449). The individual 
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contribution of each of these processes may vary from patient to patient and exhibit marked 
temporal and spatial variations (212).
A brief overview of PAH/PH epidemiology and subtypes, with a focus on those subgroups 
with a known gender bias, as well as a review of gender differences in RV adaptation across 
all forms of pulmonary vascular disease follows.
Overview of Gender Differences in PAH and PH
Gender Bias in PAH Epidemiology
The earliest modern description of idiopathic PAH by Dresdale et al. (80) in 1951 included 
three young women. The first prospective multicenter registry from the National Institutes of 
Health (NIH), which included patients with idiopathic, heritable PAH and PAH associated 
with anorexigen use, reported a mean age of 36 ± 15 years and a ratio of women:men of 
1.7:1. Before the advent of targeted PAH therapy, 1-, 3-, and 5-year survival for this cohort 
was 68%, 48%, and 34%, respectively, with an estimated median survival of 2.8 years (69). 
This early description of then “primary pulmonary hypertension,” a rare disease affecting 
young women of child-bearing age, has evolved in recent years.
The prevalence of Group 1 PAH is estimated between 15 cases/million (5.9 cases/million for 
idiopathic PAH) with an incidence of 1.1 to 3.7 cases/million/year (96, 168, 231, 318). 
Multiple registries have captured survival in both the pre- and posttreatment era (28, 69, 96, 
98, 167, 177, 185, 231, 307, 412, 487). Short-term survival has improved over time and is 
approximately 90% at 1 year and 75% at 3 years. Longer term survival remains poor, 
however, with registries survival rates between 21% and 75% at 5 years.
While a gender bias similar to that reported in the NIH registry has been noted in recent 
registries throughout the world (60, 96, 98, 158, 168, 177, 224, 231, 268, 318, 412, 450), 
others have described a more marked predominance among women. In modern registries 
including various Group 1 etiologies, as many as 70% of participants are women, and the 
average age of all participants is older (5th decade of life) (168, 185, 411, 412). A large 
European registry, which enrolled patients from 2007 to 2011 (The Comparative Prospective 
Registry of Newly Initiated Therapies for Pulmonary Hypertension [COMPERA]), 
demonstrated a ratio of 1.8 women:1 men that was most pronounced among younger 
patients (158). The largest US-based registry, the Registry to Evaluate Early And Long-term 
pulmonary arterial hypertension disease management (REVEAL), began enrolling patients 
in 2006 and reported among idiopathic PAH patients an average age of 53 ± 15 years, 80% 
of whom were women (18, 262). Whether these observations signal a true change in disease 
biology or a significant survival bias among women because of a predominantly prevalent 
(vs incident) study population is not known. In China, where targeted PAH therapies have 
only recently become available, the earliest registry of incident (i.e., untreated) patients 
included 71% women (a ratio of 2.4 women:1 men), similar to the US NIH registry (177, 
338). In a follow-up Chinese study from a treated/prevalent cohort, 76% of participants were 
women, and there were 3.1 times as many women enrolled as men (487). Table 1 
summarizes the gender biases of modern population-based registries for Group 1 PH.
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While female gender has long been established as the major clinical risk factor for PAH, in 
2010, both the French (167) and US REVEAL (28) registries published similar findings and 
found male gender to double the risk of death in PAH. This risk was shown to be 
independent of established measures of disease such as the six-minute walk distance 
(6MWD) and cardiac index (CI) (28, 167, 170). Follow-up data from REVEAL continued to 
demonstrate significant differences in outcome based on gender irrespective of whether the 
PAH diagnosis was incident or prevalent, such that 5-year survival estimates for newly 
diagnosed (incident) men were 53% ± 4% versus 63% ± 2% for women and 57% ± 2% 
versus 68% ± 1% for previously diagnosed (prevalent) men versus women (98). 
Interestingly, this survival benefit occurs despite more profound vascular remodeling and 
more plexiform lesions in PAH women (390), a constellation suggestive of better adaptation 
to vascular remodeling in women (reviewed in more detail below). Table 2 provides a 
summary of gender differences in survival, hemodynamic alterations, and treatment 
responses in PAH.
Age may be an important modifier of the relationship between gender and outcomes in PAH 
(28, 96, 167, 171, 307, 445), which suggests that temporal changes in the hormonal milieu 
may impact disease risk and severity throughout the lifespan. Among older patients, gender-
based differences in PAH prevalence appear to be diminished (158, 231, 445). In a large 
study (n = 1211) of patient-level pooled data from 11 clinical trials in PAH, women with 
idiopathic PAH and connective tissue disease (CTD)-associated PAH had more favorable 
hemodynamic indices (lower right atrial pressure [RAP], lower PVR, and higher CI) as 
compared to men with idiopathic and CTD-associated PAH (445). Younger men had higher 
mPAP than younger women, but this difference was attenuated after age 45 years. In both 
men and women with idiopathic PAH, hemodynamic burden, including mPAP, tended to 
decrease to similar levels with age, such that a gender difference in mPAP was only seen in 
patients <45 years old. Similar observations have been made in the COMPERA registry, 
which demonstrated a strong gender bias toward women among younger patients with PAH 
that dissipated after age 65 (158), and in the REVEAL registry, men had higher RAP and 
mPAP at diagnosis (as well as worse survival especially in those older than 60 years of age) 
(28, 365). These observations have not been consistent across all registries, and further work 
is needed to refine the sex-age interaction in pulmonary vascular disease (231,487).
Race/ethnicity may also modify the relationship between sex and PAH. In the NIH registry, 
the gender ratio was even more skewed toward women (4.3:1) among African Americans 
(69). This observation was also made in the United Kingdom and Ireland, where 85% of 
nonwhite patients were women (as compared to 70% women in white patients) and in the 
United States, where the ratio of women:men was 5.4:1 in African Americans from the 
REVEAL registry (18, 231).
Gender Bias in PAH Subtypes
Mutations in BMPR2, a gene encoding a member of the transforming growth factor (TGF)-β 
family, are present in 70% to 80% of families with PAH and roughly 25% to 30% of patients 
with idiopathic PAH (73, 291, 388). These mutations are transmitted in an autosomal 
dominant fashion with incomplete penetrance. Female mutation carriers are more than twice 
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as likely to be affected with PAH as carrier men (31); in a large cohort of individuals with 
BMPR2 mutations, roughly 70% of the population were women (97). Cross talk between 
BMPR2 pathways and estrogen signaling has been a major area of study as reviewed below. 
Rarer mutations in activin-like receptor kinase-1 (ALK-1), endoglin (ENG), mothers against 
decapentaplegic homologue (SMADs), caveolin 1 (CAV1), and the potassium channel 
subfamily K member 3 (KCNK3) genes have also been identified (15, 245, 302, 372). 
Recent studies identified that rare variants in ATP13A3, AQP1, and SOX17 and common 
genetic variations at loci in an enhancer near SOX17 and in HLA-DPA1/DPB1 are 
associated with PAH (129, 336). Biallelic mutations in EIF2AK4 have been linked to 
pulmonary capillary hemangiomatosis (PCH) and PVOD, very rare forms of PAH (31). 
Mutations in TBX4 are associated with childhood-onset PAH (198). The penetrance of PAH 
in these rare mutations is not known to vary by gender.
A number of systemic diseases are associated with the development of pulmonary 
vasculopathy, although the mechanisms by which PAH develops in these varied conditions 
are poorly understood. In some of these subgroups, female gender has been described as a 
risk factor for the development of PAH, including CTD-associated PAH and portopulmonary 
hypertension. Approximately 12% of systemic sclerosis (SSc) patients develop PAH, and it 
is a major cause of death (137, 295, 392). Additional CTDs such as systemic lupus 
erythematosus, mixed CTD, and rheumatoid arthritis are also associated with PAH. While 
the true prevalence of PAH in these conditions is unknown, PAH occurs less commonly than 
in SSc and is associated with better outcomes than when associated with SSc (60, 64). After 
idiopathic PAH, CTD-PAH patients are the second most represented subgroup in registry 
studies (18, 96, 168, 318). CTD-PAH patients tend to be older, have less hemodynamic 
impairment, and are more likely to have mixed phenotype PH from concurrent interstitial 
lung disease, pulmonary venous involvement, and left heart disease (18, 487). As in 
idiopathic PAH, female sex is arisk factor in CTD-PAH (18,487). CTD itself occurs more 
commonly in women than in men, and when associated with PAH patients are 3.8 to 10 
times more likely to be women (18, 60,168,185,487). Women with SSc are eight times more 
likely than men with SSc to be affected by PAH (59). While scleroderma-associated PAH is 
more common in women, it is interesting to note that PAH in scleroderma patients 
frequently does not occur until after menopause (30, 363). In patients with systemic lupus 
erythematosus, women are 17 times more likely to be affected with PAH than men (60). 
Chung et al. demonstrated an almost fourfold increase in the risk of death (hazard ratio 3.9, 
95% CI 1.1–13.9, p = 0.03) among men as compared to women with PAH associated with 
SSc (58), however.
The presence of portal hypertension without other clinical risk factors or associated 
conditions in a patient with PAH is designated as portopulmonary hypertension. This 
condition occurs in roughly 3% to 6% of patients with cirrhosis referred for liver 
transplantation (110). The French Registry reported that 40% of patients with 
portopulmonary hypertension were women (168). While the degree of cirrhosis does not 
influence the risk of portopulmonary hypertension, female gender and autoimmune hepatitis 
are independent risk factors for the development of PAH in these patients (63, 138, 195). 
Female gender as a risk factor for portopulmonary hypertension has been confirmed in 
several registry studies (168, 195, 205). Although the pathobiology of portopulmonary 
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hypertension has not been entirely elucidated, abnormalities in sex hormone signaling have 
been implicated in disease development, as discussed below (303, 340). Survival is generally 
poorer in portopulmonary hypertension than in idiopathic PAH (205).
Additional PAH subtypes and their associated conditions do not appear to have a strong 
gender bias. These include drug- and toxin-induced PAH, human immunodeficiency virus 
(HIV) infection-associated PAH, congenital heart disease (CHD)-associated PAH, and 
schistosomiasis-induced PAH. This may be because hormonal factors do not play a 
pathobiologic role in all forms of PAH or because these conditions are less well studied. 
Certain drugs and toxins have been implicated in the development of PAH, some as 
“definite” causes of PAH and others as “possible” (377). The most classic example of drug-
induced PAH are the anorexigens such as fenfluramine (1, 40, 79, 255, 339, 357, 450). 
Although tyrosine kinase inhibitors have been studied to treat PAH, the use of dasatinib for 
chronic myelogenous leukemia has been associated with the development of PAH (285, 333, 
353). Methamphetamine was recently reclassified as a “definite” cause of PAH; in one study, 
patients with methamphetamine-associated PAH were less likely to be women, had more 
severe disease, and worse outcomes as compared to patients with idiopathic PAH (486). 
Treatment with interferon has also been identified as a possible risk factor for PAH (44, 74, 
111, 178, 352, 358, 376).
The prevalence of pulmonary vascular disease in HIV-infected patients is approximately 
0.5% (308, 379, 389), which has not decreased in frequency despite the advent of 
antiretroviral therapy (379). Disease characteristics are similar to idiopathic PAH patients, 
although gender does not appear to be a risk factor for the development of PAH in HIV (168, 
321). Pulmonary vascular disease has been reported in 4% to 34% of adults with CHD (87, 
93, 242). Modern PAH registries have reported that CHD-associated PAH makes up 11% to 
24% of Group 1 PAH patients; this does not appear to vary by gender (18, 26, 96, 168, 231). 
In recent years, consensus guidelines have included a more detailed subclassification of 
pulmonary vascular disease associated with CHD, which distinguishes between precapillary/
Group 1 PAH and Group 2 PH due to congenital/acquired cardiovascular conditions leading 
to postcapillary PH (376, 377). Chronic schistosomiasis is likely the most common cause of 
PAH worldwide given the widespread prevalence of schistosomiasis mansoni infection but is 
incompletely understood. While direct pulmonary vascular exposure to egg antigens does 
not appear to cause schistosomiasis-PAH, many of the mechanistic pathways implicated in 
idiopathic PAH (e.g., TGF-β and inflammatory cytokines) have been implicated in the 
development of Schistosoma-related pulmonary vascular injury (130-132). A gender bias in 
Schistosoma-associated PAH has not been described.
Gender Bias in RV Function in PAH
Women have better RV systolic function in both health and PH, including Group 1 (PAH), 
Group 2 (left heart disease), and Group 3 (chronic lung disease/hypoxia) (192, 196, 269, 
323, 444). The Multi-Ethnic Study of Atherosclerosis (MESA)-RV is the largest population-
based, cardiovascular disease-free cohort with available RV indices measured via cardiac 
magnetic resonance imaging (MRI), the gold standard for RV assessment. Female gender 
was associated with higher right ventricular ejection fraction (RVEF), lower RV mass, and 
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smaller RV volumes after adjustment for multiple comorbid factors and body size in MESA-
RV (194, 196). These gender-based differences in RVEF and volumes were replicated in The 
Framingham Heart Study Offspring cohort (106). Both the MESA and Framingham studies 
showed age to be an important modifier of the relationships between gender and measures of 
RV morphology (106, 194, 196).
Until recently, the RV had not been robustly studied in PAH. This is important, since 
changes in RV structure and function with PAH therapies are more strongly tied to survival 
in PAH than changes in PVR (434-436). Kawut et al. demonstrated that male gender is 
associated with lower RVEF measured by radionuclide angiography in a single-center cohort 
of subjects with PAH (192). This finding has since been corroborated by several other 
investigators (175, 405). Among a Dutch cohort of 101 patients with idiopathic PAH, 
heritable PAH, or anorexigen associated PAH, men and women had similar reductions in 
PVR, but RVEF declined in men and improved in women over time with PAH therapies 
(175). A significant proportion (39%) of the transplant-free survival difference seen between 
men and women was explained by treatment-related improvements in RVEF. This suggests 
that the survival bias conferred by female gender in PAH may be explained at least in part by 
gender or sex hormone-mediated effects on the RV. These observations have led to increased 
interest in the study of sexual dimorphism in RV function and failure in PAH. Studies of 
gender differences in RV function in PAH are listed in Table 2.
Gender Bias in Treatment Responses in PAH
In addition to the observational studies reviewed above that demonstrate gender-based 
differences in PAH prevalence, RV function, and survival, differential responses to PAH-
specific treatments have also been described. In a patient-level pooled analysis from six 
randomized placebo-controlled trials of ERAs submitted to the US Food and Drug 
Administration, Gabler et al. noted that women exhibited a better response in 6MWD to 
treatment with ERAs (118). Similarly, women were more likely to respond to treatment with 
prostacyclin analogues (108). On the other hand, a post-hoc analysis of subjects enrolled in a 
trial of the phosphodiesterase type 5 inhibitor tadalafil demonstrated that men were more 
likely to improve their 6MWD and quality of life after starting tadalafil treatment as 
compared to women (258).
Gender Bias in Non-PAH PH
Studies in non-PAH PH are sparse and in general less robust than those in PAH. No clear 
signal exists indicating that female gender is a risk factor for disease development in non-
PAH PH. Heart failure with preserved ejection fraction (HFpEF) is frequently associated 
with PH and is more common in postmenopausal women (257, 359), but female gender is 
not a risk factor for HFpEF-PH per se. On the contrary, some studies exist suggesting that 
women exhibit less hypoxia-induced PH and less chronic mountain sickness than men; 
however, such effects are not consistently found across studies (39, 225, 490). Two 
retrospective studies identified male gender as a risk factor for the development of high-
altitude pulmonary edema (HAPE), a disease characterized by exaggerated and uneven 
hypoxic pulmonary vasoconstriction (HPV) (165, 386). Similar to PAH, there is evidence 
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that women with non-PAH PH demonstrate superior RV function and higher survival rates. 
A review of the Veterans Affairs Clinical Assessment Reporting and Tracking (CART) 
Program database demonstrated that in a large cohort (n = 15,464 patients) of veterans with 
all types of PH (but predominantly Group 2 and 3 PH), women exhibited higher PVR and 
PA pulse pressure, yet lower RAP (442). This constellation of findings is indicative of better 
RV adaptation despite higher RV afterload. Interestingly, women veterans with PH had 18% 
greater survival compared to men with PH. When the cohort was limited to veterans with 
precapillary PH, women with PH were 29% more likely to survive. Women are also less 
likely to develop RV dysfunction in the setting of HFpEF (269) and exhibit better RV 
function in the setting of chronic lung disease (323). No gender bias in prevalence has been 
demonstrated in CTEPH (319). In a Japanese cohort of CTEPH patients, women exhibited 
better cardiac output at baseline but higher residual PVR after pulmonary 
thrombendarterectomy (371).
Proposed Mechanisms of Gender Differences in Human PAH/PH
Taken together, the data reviewed above suggest profound gender differences in PAH and 
other types of PH (Tables 1 and 2). Female gender is one of the strongest risk factors for 
PAH development, but also a robust protective factor once the disease has been acquired. On 
the other hand, with the possible exception of PH from HFpEF, female gender does not 
appear to be a risk factor for non-PAH types of PH. In both PAH as well as non-PAH PH, 
female gender is associated with better RV adaptation, indicative of persistent gender-based 
phenotypes across various types of pulmonary vascular disease.
These findings could be due to direct effects of sex hormones on cardiopulmonary function, 
genetically determined factors, environmental or epigenetic influences, and/or cultural 
phenomena. Several lines of evidence in humans suggest that biologically relevant effects of 
sex hormones indeed play a role in mediating gender differences in the pulmonary 
vasculature and RV. First, there is a high prevalence of exposure to hormone therapy (HT) in 
women with PAH (404). Second, genetic alterations in estrogen-metabolizing enzymes and 
estrogen receptors (ERs) have been found in various forms of PAH (12, 331, 340). Third, 
17β-estradiol (E2) plasma levels correlate positively with RV function in healthy 
postmenopausal HT users yet negatively with 6MWD and functional class in PAH patients 
(19, 441, 444), and lower dehydroepiandrosterone-sulfate (DHEA-S) levels correlate with 
worse hemodynamics, RV function, 6MWD, and functional class in PAH patients (19, 441). 
Of note, lower DHEA-S levels are also associated with lower survival (19, 337). Fourth, at 
least one study described an absence of hemodynamic differences between men and women 
with PAH once they are older than 45 years, suggesting that the menopausal transition (and 
other hormone-related life cycle changes like waning testosterone and/or DHEA) may 
modify disease risk (445). In addition, as mentioned above, menopause represents a risk 
factor for the development of PAH in scleroderma patients, while HT may attenuate the risk 
of PAH in these patients (30, 363). Lastly, genetic variations in 17β-estradiol metabolism 
and androgen signaling are associated with RV morphology in a gender-specific manner in 
cohort of subjects without clinical cardiovascular disease (MESA-RV) (443). The 
contributions of sex hormones in human PAH/PH will be reviewed in detail within this 
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article. The roles of genetics, epigenetics, environmental exposures, and cultural factors have 
been much less well studied and represent a significant knowledge gap in the field.
The “Estrogen Puzzle” in PAH
The marked discrepancy between increased susceptibility to PAH among women on the one 
hand and better disease outcomes in women on the other hand has been described as the 
“estrogen paradox” and has been the topic of many editorials, reviews, and discussions at 
scientific meetings. A second “estrogen paradox” has been identified in the area of basic and 
cellular investigation. In particular, this refers to the finding that estrogens are protective 
against disease development in several animal models of PAH, but detrimental (disease 
promoting) in others. Lastly, some investigators refer to a paradox in the observation that 
estrogens have been uniformly shown to be cardioprotective in the RV, whereas in the 
pulmonary vasculature they may exert disease-promoting effects. Together, these 
inconsistencies have led to increased interest in the study of sexual dimorphism in PAH and 
RV failure. However, since the term “paradox” implies an observation or finding that is 
logically unacceptable or self-contradictory, we prefer the terms “estrogen puzzle” or 
“estrogen conundrum.” This is based on the rationale that we believe biological explanations 
exist for the observed sex/gender differences in PAH but have not yet been fully identified. 
For example, many “paradoxical” effects can be explained with dose-, timing-, or 
compartment-specific effects of estrogen. We would also argue that to focus solely on 
estrogen as the hormone of interest is too narrow a scope. While estrogens clearly have been 
implicated as clinically important disease modifiers in PAH, one should note that estrogen-
independent factors, such as other sex hormones, sex chromosomes, genetics, and 
epidemiological factors, likely play significant roles as well.
Sex Differences in Animal Models of PAH
Much of the knowledge about mechanisms of gender and sex differences in PAH and PH has 
been obtained from the study of animal models. While several animal models have been 
developed that display features of the pulmonary vascular remodeling and/or right heart 
hypertrophy/failure that are common to PAH, recapitulating the sexually dimorphic disease 
presentation and progression in these models has been challenging. In contrast to human 
PAH, female sex is protective in many classical models of PAH, such as hypoxia- or 
monocrotaline (MCT)-induced PH. However, several models (many of them transgenic) 
have been developed over the past two decades that demonstrate a female bias with regard to 
disease susceptibility or severity, and animal studies have allowed for a more nuanced 
understanding of the effects of sex and sex hormones on disease development. In addition, 
progress has been made in understanding sex differences in RV function and failure. 
Commonly used animal models of PH and RV failure have been reviewed extensively 
elsewhere (126, 212, 347, 394). Here, we briefly describe each model of PAH and the 
impact of sex on pulmonary and RV remodeling.
A synopsis is provided in Table 3. Contributions of individual sex hormones to PH 
development in these models and their interactions with specific pathways will be described 
later in this article.
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Chronic Hypoxia-Induced Pulmonary Hypertension (HPH)
Hypoxia has classically been used in both rodent and non-rodent models to induce 
pulmonary vascular remodeling. Histologically, HPH (hypoxia-induced pulmonary hyper-
tension) induces media hypertrophy in the pulmonary vasculature, but plexiform or vaso-
occlusive lesions are not seen (394). In addition, damage to the pulmonary vasculature is 
reversible after reexposure to room air, and this model induces RV hypertrophy but not 
failure (212, 393). While hypoxia alone does not recapitulate Group 1 PAH pathology, HPH 
shares certain signaling pathways and disease mechanisms with human PAH and could be 
considered a model of mild or early PAH (393). Some investigators, on the other hand, 
suggest that HPH may be a better model for Group 3 PH (345). Contrary to human data, 
females of many HPH model species are more resistant to HPH, with smaller increases in 
right ventricular systolic pressure (RVSP), RV hypertrophy, and pulmonary vascular 
remodeling. This effect has been shown in vivo in rats, mice, swine, and chickens (42, 92, 
208, 267, 327, 335, 350), as well as in isolated ovine lungs, which display reduced HPV 
(459, 460). Reduced HPV has also been demonstrated in isolated pulmonary arteries (PAs) 
from female rats (214). While the mechanisms of contraction during the acute phase of HPV 
are separate from the mechanisms governing contraction and remodeling during chronic 
HPH, the observation that sex impacts the contractile response of isolated pulmonary vessels 
illustrates the dramatic sexual dimorphism of tissues implicated in PH pathogenesis. The in 
vivo data in rats is particularly compelling, as ovariectomized rats become vulnerable to 
severe HPH, and supplemental E2 treatment in ovariectomized animals rescues this effect 
(92, 335). HPH is driven in part by hypoxia-induced erythrocytosis (which leads to increased 
blood viscosity and increases in PA pressure) (299, 437), and it has been demonstrated that 
the female resilience in HPH is at least in part due to lower hematocrit levels (208, 296). 
However, direct effects on the pulmonary vasculature (less vasoconstriction and remodeling) 
play a role as well. Compared with rats, mice are relatively resistant to HPH regardless of 
sex (126, 161, 406). Nevertheless, female HPH mice also display more favorable 
hemodynamics, less RV hypertrophy, and less PA remodeling (478, 479). While favorable 
hemodynamics and decreased RV hypertrophy are akin to humans, decreased PA remodeling 
is not. Female HPH mice also express higher levels of angiogenic factors such as VEGF-A 
in the RV as compared with hypoxic males (35).
Monocrotaline-Induced PH (MCT-PH)
Administration of the toxic pyrrolizidine alkaloid MCT in rats is another classical model of 
PAH. Circulating MCT is converted to its bioactive form dehydromonocrotaline by the 
cytochrome P450 (CYP) enzyme CYP3A family in the liver (189). The exact mechanism 
through which dehydromonocrotaline induces PH is unknown, but it likely acts primarily 
through damage to pulmonary artery endothelial cells (PAECs) (342). For reasons that are 
not entirely clear, this model does not work in mice; this may be due to unpredictable 
CYP3A subtype 4 activity and/or species-specific resistance to MCT-induced vascular injury 
(127). Muscularization of PAs, increased PVR, RV hypertrophy, and eventual RV failure and 
death are seen in this model. MCT-PH is accompanied by systemic inflammation and 
possibly myocarditis and hepatic veno-occlusive disease and has therefore been proposed as 
a model of inflammation-induced PAH, such as PAH associated with CTD (127). Similar to 
findings in hypoxia, female sex is protective in the rat model of MCT-PH. Specifically, 
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female sex or exogenous estrogens ameliorate the phenotype of MCT-PH compared with 
males, while ovariectomy (OVX) exacerbates disease progress (3, 99, 298, 421, 432, 483). 
Sex differences in the MCT model may result at least in part from decreased CYP3A activity 
in the female liver, leading to reduced levels of dehydromonocrotaline (189). Recently, MCT 
administration has been combined with chronic hypoxia to develop a more severe phenotype 
of PH, characterized by thrombotic, neointimal, and plexiform-like lesions in the pulmonary 
vasculature (66, 289). Only data from male rats has been published using this combined 
injury model. Similarly, MCT in combination with pneumonectomy causes more severe PH 
and vascular remodeling but has only been published in males (466).
Sugen/Hypoxia-Induced PH (SuHx-PH)
A more recent model of PAH was published in 2001, which more closely resembles the 
human phenotype (409). Here, administration of the vascular endothelial growth factor 
(VEGF) receptor 2 antagonist Su5416 (sugen) to young rats, followed by hypoxia and 
subsequent reexposure to normoxia produces severe PH with RV failure and mortality. In 
this model, Su5416 administration leads to initial PAEC apoptosis, followed by exuberant 
proliferation of the remaining PAECs, resulting in pronounced and progressive PA 
remodeling and formation of vaso-occlusive lesions (409). Two recent studies demonstrated 
that female sugen/hypoxia-induced pulmonary hypertension (SuHx-PH) rats exhibit better 
RV function than their male counterparts (both at rest and after acute exercise), including 
improved stroke volume index, CI, RV compliance, and reduced RV hypertrophy (114,213). 
These findings were accompanied by more favorable antioxidant, pro-survival, and pro-
angiogenic responses as well as less fibrosis and lower pro-inflammatory cytokine 
expression in female RVs. Interestingly, higher cardiac indices were also noted in healthy 
females versus males, mirroring the better RV function noted in healthy humans (167, 175, 
192, 405). In both studies, no sex differences were found in RVSP increase or pulmonary 
vascular remodeling (114, 213). A study by Rafikova et al. (330), on the other hand, 
demonstrated sexually dimorphic pathology in the pulmonary vasculature, with female 
SuHx-PH rats displaying increased pulmonary vascular wall thickness compared to male 
SuHx-PH animals. However, the pulmonary vasculature from male SuHx-PH rats displayed 
increased fibrosis and inflammatory markers, and female SuHx-PH rats displayed less RV 
hypertrophy and increased survival (330). Taken together, these studies show that SuHx-PH 
exhibits sexually dimorphic features in rats, with better RV adaptation and survival in 
females, despite potentially more pronounced vascular remodeling. Importantly, this mirrors 
the human PAH phenotype and suggests that SuHx-PH is a suitable model to study sex 
differences. The lung vascular remodeling, fibrosis, and inflammation data by Rafikova et al. 
suggest that sex differences in the pulmonary vasculature can be nuanced and that a detailed 
examination of different compartments and pathways is necessary to capture the full 
spectrum of sex differences in the lung vasculature in experimental PH and human PAH. 
SuHx-PH has also been employed in mice, albeit with a less-consistent and less-severe 
phenotype (126, 212, 347, 394). Induction of SuHx-PH in mice requires maintained hypoxia 
as well as weekly injections of Su5416. In the only published male-female comparison in 
SuHx-PH mice, no sex differences were noted in RVSP or RV hypertrophy (61).
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Mutant and Transgenic Rodent Strains
Genetically modified rodents have produced mixed and occasionally contradictory findings 
in regard to sex-based differences in PH. While some models display a female bias, others 
show the opposite. For example, overexpression of the calcium-binding protein S100A4/
Mts1 (72) or the serotonin transporter SERT (462, 464) increases female penetrance of PH 
and disease severity, while ovariectomy attenuates these effects. Disease outcomes are 
similarly more severe in female mice globally lacking the epoxygenase CYP2c44 (182) or 
lacking the transcription factor Stat5 in SMCs (479). Conversely, female mice lacking genes 
for vasoactive intestinal peptide (VIP) (349), endothelial nitric oxide synthase (eNOS) (278), 
or apolipoprotein E (ApoE) (the latter in combination with a high-fat diet) (147) develop a 
much less-severe PH phenotype compared with male littermates. Furthermore, hypoxic 
female miR-214 knockout mice develop similar hemodynamic and PA remodeling 
alterations as their male counterparts but exhibit less RV hypertrophy (395). Two studies 
demonstrated that certain transgenic manipulations can abolish the male bias in experimental 
PH, suggesting that these pathways may be involved in making males more susceptible or 
females less susceptible. Specifically, smooth muscle-specific deletion of Stat5 (479) or the 
transcriptional repressor Bcl6 (478) abrogates female protection in female rats with HPH. In 
the case of Stat5 deletion, female protection is reversed to female susceptibility.
As mutations in BMPR2 underlie most cases of heritable PAH, and since decreased BMPR2 
activation has been noted in idiopathic PAH (246), several strains of Bmpr2 mutant mice 
have been developed to examine the role of this signaling pathway in disease progression 
(reviewed in Ref. 345). Global knockout of the Bmpr2 gene is embryonically lethal in mice, 
while heterozygous mutant mice spontaneously develop a mild form of PH (29). Targeted 
deletion of Bmpr2 in either ECs (160) or SMCs (458) is sufficient to produce PH features 
such as increased RVSP and pulmonary vascular remodeling. A recent report from Hautefort 
et al. describes a similar phenotype in Bmpr2 mutant rats (150). A gender bias has not been 
reported in Bmpr2 mutants, with similar penetrance of PH seen in both male and female 
mice. However, Bmpr2 mutant mice are more vulnerable to 16-OHE1 administration than 
wild-type controls, leading to increased PH penetrance (52). This phenomenon is associated 
with aberrant estrogen signaling within cells of the pulmonary vasculature (101). Even 
though there appear to be no sexually dimorphic features in Bmpr2 mutant strains, altered 
estrogen signaling in Bmpr2 mutants may be relevant to unraveling the estrogen puzzle in 
human PAH.
While these transgenic mouse models allow focused hypothesis testing regarding the role of 
a particular gene/protein in PH and are useful in identifying mechanisms that may explain 
sex differences in PH, it is important to remember that many transgenic models display only 
a mild hemodynamic or vascular phenotype of PH, thus limiting their clinical relevance (24). 
Additionally, knockout models are primarily available in mice, which generally display a 
less-severe PH phenotype than rats, and robust models of PH such as MCT or SuHx either 
do not work in mice (in the case of MCT) or result in only a mild phenotype (in the case of 
SuHx) (61, 126). Despite these caveats, transgenic mouse models have been successfully 
used to investigate the estrogen puzzle and have advanced the field. Recent advances in 
genetic manipulation such as CRISPR/Cas9 are increasing the number of available 
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transgenic rat strains (105); this generates an exciting opportunity to perform gain- and loss-
of-function studies in more robust PH models.
Rodent Models of Immunity and PH
Two studies have been published employing T-cell-deficient athymic rnu/rnu rats. In the first 
study, administration of the VEGFR 1 and 2 antagonist semaxanib induced more severe PA 
remodeling, more RV hypertrophy, and more profound RV systolic dysfunction in males 
relative to females (135). Impairment of RV-PA coupling efficiency was observed only in 
males, and pulmonary artery smooth muscle cells (PASMCs) switched from a contractile 
state to a dedifferentiated state in males only. However, a more recent study demonstrated 
the opposite effect (408). Here, sugen administration or chronic hypoxia led to a more severe 
phenotype in female rats. In particular, female rats exhibited greater pulmonary 
inflammation; augmented RV fibrosis; lower plasma levels of prostacyclin; decreased lung 
expression of cyclooxygenase, prostacyclin synthase, programmed death ligand-1 (PDL-1), 
and heme oxygenase-1; and reduced PDL-1 levels in the RV. Treg immune reconstitution 
protected against PH development in both sexes and abrogated sex differences in Treg-
deficient animals. While the reason for the contradictory findings between the two studies in 
athymic rats is unclear and must be resolved, the implication that immunity may underlie 
sex differences in PH is intriguing and parallels data showing sex- and sex hormone-
mediated differences in immune function and dysfunction (227) and studies that identify 
immune dysregulation as a contributing factor to PAH in humans (328). More studies are 
required to investigate the interplay among sex, sex hormones, and immunity in PAH/PH. 
Ultimately, such studies would be expected to shed further light on the underlying 
mechanisms of sex differences in experimental PH and human PAH.
A critical role of immune cells in PH was recently demonstrated by Hu et al. in a study 
where humanized mice were engrafted with human hematopoietic CD34+ progenitor cells 
(resulting in circulating human leukocytes) and subsequently exposed to chronic hypoxia. In 
contrast to nonhumanized mice, humanized mice displayed significantly increased RVSP 
and PA muscularization (163), suggesting that species-specific immune responses may 
underlie the reduced acuity of murine PH models at least in part.
Drug-Induced PH
While gender does not play a clear role in human drug- and toxin-induced PAH (perhaps 
because of psychosocial or behavior influences), two models of drug-induced PAH 
predominantly affect female rodents. Specifically, administration of the anorexigen 
dexfenfluramine or the industrial compound 4,4′-diaminodiphenylmethane (DAPM) results 
in PH in female animals only (46, 71). The mechanism of both drugs appears to involve 
increased serotonergic signaling and altered estrogen metabolism to favor pro-proliferative 
metabolites. Interestingly, dexfenfluramine-induced PH involves upregulation of the 
estrogen-metabolizing enzyme CYP1B1, and CYP1B1 knockout animals are not susceptible 
to dexfenfluramine-induced PH (71).
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Pulmonary Artery Banding (PAB)
Pulmonary artery banding (PAB) is a model of RV hypertrophy with or without RV failure 
that is independent of changes in the pulmonary vasculature (212). No investigations 
focusing on sex differences in this model have been published to date.
Summary of Studies of Sex as a Disease Modifier in Animal Models
Taken together, animal models have identified sex as an important disease modifier in 
experimental PH. As in humans, animal models of PAH demonstrate an effect of sex on 
disease penetrance and severity. As in humans, the results from animal models can be 
complex and occasionally contradictory. In the classical models of PAH (HPH and MCT-
PH), female sex is protective. Female sex is also protective in several transgenic mouse 
models. On the other hand, a female bias with regard to disease susceptibility or severity has 
been noted in transgenic mice, Treg-deficient rats and models of drug exposure. SuHx-PH 
rats exhibit complex sex-specific features in the pulmonary vasculature but better RV 
function and survival in females. It is worth noting, however, that the pulmonary 
hypertensive or RV failure phenotype in some of these models is modest, thus limiting their 
relevance to human PAH. In particular, results from studies in mice may be of limited 
translational value because of the mild PH phenotype produced. New animal models, 
including transgenic, immunological, pharmacological, and surgical models that employ 
various “hits” to the pulmonary vasculature rather than one single insult (thus mimicking the 
pathogenesis of human PAH) are likely to provide novel information on the role of sex in PH 
(212). For example, SuHx-PH rats recapitulate many of the hallmarks of human PAH (126, 
212, 347, 394). However, it is critical to look at animal models as tools to dissect specific 
components or mechanisms of disease development rather than use one single model to 
represent and study the entire spectrum of gender differences in human PAH (38, 324). In 
addition, important modifiers such as animal age, phase of the estrous cycle, and external 
influences (e.g., dietary phytoestrogens (149) and gender of the animal handler (387)) need 
to be considered. Only the study of several animal models in conjunction and the 
consideration of these modifiers will generate sufficient and relevant new data to solve the 
estrogen puzzle.
What are Possible Explanations for Discrepancies in Sex/Gender 
Differences and Sex Hormone Effects between Rodent Models and Human 
PAH?
While the animal models described here recapitulate many features of PAH, no animal 
model is a perfect analog for human physiology. Animal models of estrogen signaling are 
particularly difficult as the human menstrual cycle is a radically different physiological 
phenomenon than the much shorter estrous cycles of laboratory animal rodents (356). 
Hormone levels, cycle duration, and the aging endocrine profile are all species specific and 
may play a vital role in PAH/PH penetrance and progression. These differences may 
underlie seemingly contradictory findings, such as an association of high E2 levels with PH 
in humans (19, 441, 471), but reduced E2 levels in rodent models of PH (114, 482). It is 
possible that PAH/PH alters hormone metabolism and secretion differently between humans 
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and model species and that the profile of estrogen metabolite production and distribution is 
different between species. The nature and physiological impact of increased E2 levels in 
human PAH patients is also unclear. Without a baseline endocrine profile that predates 
disease onset, it is impossible to tell if increased E2 levels are a result of PAH onset or if 
elevated E2 levels instead directly contribute to PAH development. Also, because hormone 
secretion is controlled via a negative feedback mechanism at the level of the hypothalamus 
and pituitary, it is possible that impaired ER signaling could lead to a surplus of circulating 
hormone in the circulation. In this scenario, elevated E2 may be serving as a biomarker of 
impaired downstream signaling, rather than as a disease mediator per se. More detailed 
investigations into hormone metabolism and species-specific endocrine profiles are 
warranted to develop new models of PAH that more closely align with human physiology.
What are the Underlying Mechanisms Mediating Sex and Gender 
Differences in Rodent Models and Human PAH?
The data reviewed above clearly demonstrate that profound gender and sex differences exist 
in human PAH and PH as well as in experimental PH. Substantial research over the past two 
decades has identified sex hormone-dependent and -independent mechanisms as mediators 
of these differences. The latter include genetic, epigenetic, environmental, and behavioral 
factors. In the remainder of this article, we review sex hormone-dependent and -independent 
factors involved in sex and gender differences in etiology, physiology, hemodynamics, 
treatment responses, and outcomes in PAH and PH. Given the critical role of RV function in 
PAH, we highlight sex and gender differences in RV function in dedicated s. Since the 
majority of the published literature involves data on estrogen signaling and metabolism, a 
large part of this article will focus on this area, but we also discuss the currently available 
knowledge about testosterone, progesterone, and DHEA(-S) as well as genetic, 
environmental, and behavioral modifiers. The conglomerate of the data reviewed 
demonstrates that there has been significant progress in the field and that we are getting 
closer to solving the “gender puzzle” in PAH and PH.
Overview of Sex Hormone Synthesis and Metabolism
Detailed reviews of steroid hormone production and metabolism are available in the 
literature (317, 417) and are beyond the scope of this article. However, since basic concepts 
of steroidogenesis and sex hormone signaling are key to understanding the sexually 
dimorphic pathogenesis and presentation of PAH/PH, clinically important key concepts will 
be reviewed here. The steroidogenic pathway is illustrated in Figure 3.
All steroid hormones are derived from cholesterol, a 27-carbon sterol consisting of four 
hydrocarbon rings attached to a hydrocarbon tail (top left in Figure 3). Sex hormone 
synthesis is characterized by the progressive cleavage of carbon atoms surrounding the 
hydrocarbon ring structure. Sex hormones can therefore be broken into three classes based 
on the number of carbon atoms present in their structure: 21-C, 19-C, and 18-C hormones 
(green, blue, and pink boxes, respectively, in Figure 3). Hormone synthesis and modification 
within each of these classes will be briefly discussed before examining the role of specific 
sex hormones in PAH/PH.
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In the first step of steroidogenesis (Figure 3), CYP11A (side-chain cleavage enzyme) cleaves 
the hydrocarbon tail from cholesterol to yield pregnenolone, a 21-carbon compound that is 
the common precursor of all steroid hormones. CYP11A is located on the inner 
mitochondrial membrane, and transport of cholesterol across the outer mitochondrial 
membrane by steroidogenic acute regulatory (StAR) protein is the rate-limiting step in 
steroid hormone synthesis (396). The enzyme 3β-hydroxysteroid dehydrogenase (3β-HSD) 
converts pregnenolone to progesterone, a biologically active steroid critical to establish and 
maintain pregnancy. Progesterone is primarily secreted by the ovary and placenta, but also 
serves as a metabolic intermediary in the adrenal gland. The role of progesterone in PAH/PH 
is a fairly unexplored avenue of research that will be discussed later.
CYP17A catalyzes conversion of either pregnenolone or progesterone to the 19-carbon 
hormones dehydroepiandrosterone (DHEA) or androstenedione, respectively (blue box in 
Figure 3). Circulating DHEA and its sulfate ester DHEA-S are the most abundant steroid 
hormones in the human body (252). DHEA can be converted to the weak androgens 
androstenedione or androstenediol, both of which are immediate precursors of the potent 
androgen testosterone. The enzyme 5a-reductase converts testosterone to 
dihydrotestosterone (DHT), the most potent biological androgen.
18-Carbon steroid hormones (estrogens) are derived from androstenedione or testosterone. 
CYP19 (aromatase) catalyzes the conversion of androstenedione or testosterone into estrone 
(E1) or estradiol (E2), respectively (pink box in Figure 3). Estrone may be converted to 
estradiol through the action of 17β-hydroxysteroid dehydrogenase (17β-HSD). Estrogens 
may be further processed into bioactive metabolites via hydroxylation by multiple CYP 
enzymes including CYP1A1 and CYP1B1. The resulting hydroxyestrogens may then 
undergo methylation by the enzyme catechol-O-methyl transferase (COMT) to form 
methoxyestrogens (220, 427, 476). One hydroxylated metabolite, 16α-hydroxyestradiol, is 
commonly referred to as estriol (E3), an estrogenic compound that plays an important role 
during pregnancy (4, 310). The various estrogen metabolites exert radically different effects 
on cell signaling and function that may impact many proliferative and inflammatory 
processes, such as cancer, chronic inflammatory diseases, and PAH (86). The role of these 
metabolites in PAH is described in the following section. Sex steroids typically signal 
through specific receptors (e.g., progesterone-, androgen-, and estrogen-receptors), even 
though receptor-independent actions of certain metabolites have been described as well 
(described in detail later).
Circulating hormone levels vary widely among individuals and tend to decline with age 
(Table 4). Women of reproductive age also exhibit cyclical surges and withdrawal of 
estrogens and progesterone according to the phase of each menstrual cycle. Pregnancy and 
menopause are marked by their own distinct endocrine profiles. While serum hormone levels 
are constantly in flux, a high proportion of circulating sex hormones are bound to carrier 
proteins such as albumin or sex hormone-binding globulin (SHBG), which sequester 
hormones from receptors in surrounding tissues. This results in a relatively small percentage 
of circulating hormones being biologically active (143). Further complicating the issue, 
many nongonadal tissues contain the necessary enzymes (e.g., 3β-HSD, 17β-HSD, and 
aromatase) to synthesize both androgens and estrogens from DHEA. Peripheral production 
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of androgens and/or estrogens is possible in many organs and occurs in adipocytes, ECs, 
SMCs, cardiac fibroblasts, and cardiomyocytes (148, 197, 314, 317, 465, 480). Peripheral 
aromatization to form E1 and E2 is particularly important as this is the main source of 
estrogens in men and post-menopausal women (183, 378). Local production of steroids by a 
target cell has been termed “intracrinology” (207, 360). This is biologically and clinically 
relevant as it may lead to significant local steroid signaling not reflected in measurements of 
circulating hormone levels.
Gauging the effect of sex and sex hormones on physiology is complex due to conversion 
between hormone classes, changing levels of bioactivity, steroid metabolism into other 
bioactive compounds, and hormone synthesis in nonclassical steroidogenic tissues. In target 
cells, changes in hormone-receptor isotype abundance or localization (91, 294, 325, 355), 
variations in activity of enzymes responsible for sex hormone synthesis (47, 202, 253), 
interactions with genomic and nongenomic cofactors (265), additive or opposing effects of 
multiple hormones or receptors (142, 191), and epigenetic phenomena (219) can drastically 
alter the downstream effect of hormone-receptor binding. At a broader level, the expression 
and activity of sex steroid receptors, as well as hormone-metabolizing enzymes, may be 
affected by sex, age, diet, environmental exposures, fluctuations in endogenous sex hormone 
levels (e.g., menstrual cycle and menopause), and various disease states (reviewed in Ref. 
297). It is therefore not surprising that many sex hormone-mediated effects are 
compartment-, time-, and concentration dependent. Carefully devised experimental systems 
are required to determine the impact of steroid hormones, particularly in a complicated 
syndrome like PH. The development of new animal models, new biological tools, and the 
dedication of many researchers has allowed recent advances in unraveling the role of steroid 
hormones in PAH/PH and moved the field closer to unraveling the “estrogen puzzle” in 
PAH.
Estrogen in PH
Estrogen Signaling and Metabolism
E1, E2, and E3 are the three main estrogens in the human body. Of these, E2 is the most 
potent estrogen and the primary mediator of estrogen signaling. An overview of E2 levels in 
humans across the life span is provided in Table 4. E1, E2, and E3, as well as many of their 
metabolites, signal through interaction with three ERs. Two of these receptors, ERα and 
ERβ, are members of the nuclear receptor superfamily (reviewed in Refs. 151, 271, 272, 
297, 375). ERα and ERβ are encoded by independent genes located on separate 
chromosomes. In humans, ESR1 (estrogen receptor α gene) encodes ERα, a protein 
composed of 595 amino acid residues with a molecular weight of 66.2 kDa. ESR2 (estrogen 
receptor β gene) encodes ERβ, a slightly smaller protein composed of 530 amino acids and a 
molecular weight of 59.2 kDa (305). The two receptors share high homology for the DNA-
binding domain, as well as the ligand-binding domain (95% and 60%, respectively) (206). 
Both receptors also contain two activation function domains (AF-1/AF-2) which alter 
transcription through interaction with nuclear coactivators/repressors (201, 454). ERα and 
ERβ share less than 30% homology of the AF domains, which contributes to the unique 
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transcriptional profile of each receptor despite near-perfect homology of the DNA-binding 
domain (488).
ERα and ERβ are widely expressed throughout the body (reproductive, cardiovascular, 
respiratory, central nervous, endocrine, immune, and skeletal systems). In the pulmonary 
vasculature, ERα and ERβ are expressed in PAECs (141, 439, 440), PASMCs (141, 187), 
and fibroblasts (78), all of which are involved in vascular remodeling during PH. ERs are 
also expressed in other lung cells including epithelial cells (141, 176), alveolar cells (315), 
and alveolar macrophages (401, 439). In the heart, ERα and ERβ are expressed in ECs, 
cardiomyocytes, and fibroblasts (reviewed in Refs. 271, 272). ERα and ERβ are also 
expressed in progenitor cells (140) and immune cells (204, 397), where they modify 
developmental, regenerative, and immune signaling processes in health and disease. While 
there is overlap in functions of ERα and ERβ, significant differences exist between the two 
ERs in tissue expression and function.
Classical estrogen signaling occurs via these two receptors in what is termed the genomic 
pathway. Here, estrogen diffuses through the cell membrane and binds to cytoplasmic ERα 
or ERβ. This estrogen-ER complex subsequently dimerizes with another estrogen-ER 
complex (either as a homo- or heterodimer) and translocates to the nucleus. The estrogen-ER 
dimer then binds to an estrogen responsive element (ERE) in the DNA. In this context, 
estrogen acts as a classic transcription factor to alter gene expression. Coactivators and 
corepressors of gene transcription interact with the estrogen-ER complex and contribute to 
regulating gene expression. In a variation of this pathway, referred to as tethered estrogen 
signaling, the estrogen-ER complex indirectly regulates gene expression by binding to and 
modulating the activity of other transcription factors. In a third pathway, nonestrogen ligands 
such as epidermal growth factor phosphorylate and activate cytoplasmic ER in the absence 
of ER binding (67). Lastly, estrogens can bind to ERα and ERβ anchored to the cell 
membrane. Activation of these membrane-bound receptors leads to rapid, nongenomic 
cellular effects. In this signaling pathway, estrogen binds to a membrane-bound receptor, 
leading to activation of a second messenger such as MAPK (367). This pathway does not 
require altered gene transcription and can induce rapid and diverse cellular effects such as 
ion channel activation, or activation of eNOS or prostacyclin synthase (374). Nongenomic 
signaling occurs within seconds to minutes and is particularly important in the 
cardiovascular and respiratory systems (16, 49, 53, 157, 367, 370, 402, 481). While 
nongenomic estrogen signaling initiates rapid dynamic cellular responses, this pathway may 
also ultimately produce changes in gene transcription through activation and 
phosphorylation of downstream transcription factors and activators (33, 151, 297). A third 
ER, GPR30 (G-protein-coupled receptor 30), is a G-protein-coupled receptor that has been 
shown to bind estrogen and signal exclusively through the nongenomic pathway.
Estrogen signaling can be altered by changes to either the ligand or receptor. Each 
endogenous estrogen (E1, E2, and E3) has a unique ER affinity, and the downstream effects 
of estrogen signaling also depend on the type of ER (ERα, ERβ, and GPR30), their 
interactions with each other, and their tissue-specific expression patterns. Both circulating 
estrogen levels and ER expression patterns change based on sex, age, disease state, and 
fluctuations during the menstrual cycle (reviewed in Ref. 297). Changes in ER 
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ubiquitination can increase proteosomal degradation of ERs, while posttranslational 
modifications including methylation, acetylation, or S-nitrosylation may drastically impact 
ER signaling. In the genomic pathway, nuclear coactivators and corepressors may alter 
transcription by interacting with the ER in the nucleus (264). One final modulator of ER 
signaling is the existence of several ER splice variants. These variants demonstrate a range 
of activity during in vitro studies from constitutive activation to dominant-negative 
regulation of ER signaling (156). A relative increase in the expression of ER splice variants 
(as a percentage of total ER isoforms) is associated with human disease pathology, 
particularly tumorigenesis (156,410). The role of ER splice variants has not been 
investigated in PH.
E1 or E2 may be further metabolized to form new bioactive compounds, usually by 
hydroxylation at carbon 2, 4, or 16. The 2-hydroxylation pathway transiently produces 2-
hydroxyestradiol (2-OHE2) or 2-hydroxyestrone (2-OHE1) before conversion to 
methoxyestrogens by the enzyme COMT (220, 427, 476). 2-Methoxyestradiol (2-ME2) is a 
potent metabolite with no ER affinity, which displays antimitogenic and proapoptotic 
properties in both tumor (215, 322, 362) and vascular SMCs (82, 428, 484). All enzymes 
necessary for conversion of E2 to 2-ME2 (CYP1A1/2, CYP1B1, and COMT) are present in 
cardiovascular tissue, and 2-ME2 synthesis occurs in vascular ECs and SMCs (81, 82, 220, 
417, 485). In contrast to the antimitogenic, nonestrogenic metabolites resulting from the 2-
hydoxylation pathway, the 16-hydroxylation pathway produces 16α-hydroxyestradiol (E3) 
or 16α-hydroxyestrone (16α-OHE1). While E3 is a weak estrogen, 16α-OHE1 exerts 
comparable estrogenic effects to E2 (103) and promotes inflammatory, proliferative, and 
angiogenic cellular processes (417). 16α-OHE1 has lower affinity for SHBG than E2 and 
may covalently bind to ERs causing hyperestrogenic signaling (103, 403, 417). Several 
CYP450 isoforms are capable of catalyzing 16α-hydroxylation (17), and the enzyme 
CYP1B1 has been the primary focus of PAH research. CYP1B1 is expressed in 
cardiovascular tissue (314) and is upregulated in PASMCs in several animal models of PAH 
(71, 179). Because of its pro-mitogenic properties, 16α-OHE1 is currently explored as a 
therapeutic target in clinical trials for various cancers (e.g., NCT02525159). The role of 
CYP1B1 and 16α-OHE1 metabolism in PAH is currently under investigation and will be 
discussed in detail later in this article. A minor pathway of estrogen metabolism is the 4-
hydroxylation pathway, leading to the formation of 4-hydroxyestradiol (4-OHE2), which 
exerts estrogenic and carcinogenic effects (54, 228, 417). It should be noted that the 
biological effects and properties of estrogen metabolites have primarily been explored in 
reproductive, endocrine, and malignant tissues and that several of the reported effects may 
be tissue-, time-, and/or context dependent and have not been fully explored in the 
cardiopulmonary system. The ratio of various hormones and metabolites may also be more 
important for net biological effects than the absolute levels of one single hormone (145).
Estrogen in the Pulmonary Vasculature
Cell Culture and Animal Studies—In the systemic vasculature, estrogen signaling 
promotes healthy vessel function and is protective in the face of disease or vascular injury 
(48, 136, 313,425,470). In particular, ERα facilitates EC recovery after vascular injury, 
blocks monocyte adhesion to ECs, and inhibits vasoconstrictor responses (32, 36, 244, 313, 
Hester et al. Page 21













381, 467, 475). Furthermore, loss-of-function mutations in ESR1 have been linked to 
endothelial dysfunction, coronary artery disease, myocardial infarction, and stroke (361, 
368, 369, 398, 399). Many studies support a similar role of estrogen and its receptors in the 
pulmonary vasculature. Both ERα and ERβ activation in cultured PAECs increases eNOS 
activity (49, 157, 216, 247, 370), while ERβ-mediated signaling has been shown to increase 
prostacyclin synthesis (247). Increased activation and synthesis of these potent vasodilators 
suggests that estrogen signaling in PAECs promotes vasodilation. Indeed, endogenous (214) 
or exogenous (210) estrogen exposure attenuates both phenylephrine-induced 
vasoconstriction and HPV in isolated rat PA rings. These effects were later shown to be 
mediated by specific ER isoforms as the ERa-agonist propylpyrazole triol (PPT) attenuates 
phenylephrine-induced vasoconstriction, while the ERβ agonist DPN (diarylpropionitrile) 
ameliorates HPV (209). Inhibition of eNOS eliminates the vasodilatory effect of both ERα 
and ERβ, indicating that NO plays a central role in estrogen’s effect in the pulmonary 
vasculature (209). Several other groups have demonstrated that estrogens, and in particular 
E2, attenuate HPV (116, 210, 211, 214,473) (see Table 5 for details).
The Estrogen Puzzle in Animal Models of PAH—Studies in classic (HPH and MCT) 
animal models of PH have shown that estrogen ameliorates the progression of PH in the 
pulmonary vasculature, a finding that is not surprising given the protective role of female sex 
in these animal models. The SuHx-PH rodent models have produced seemingly 
contradictory findings as both estrogen administration and estrogen antagonism have been 
shown to ameliorate PH outcomes. Still other research models have identified estrogen as a 
potent disease mediator in the pulmonary vasculature. In the following sections, we review 
what is known about estrogen’s effect in the lung during PH progression, followed by a 
summary of estrogen’s effects on the RV. The results of studies focusing on bioactive 
estrogen metabolites will be discussed separately. An overview of the major studies of E2 
signaling in experimental PH is provided in Table 5.
Animal Studies Demonstrating Protective Estrogen Effects in the Pulmonary 
Vasculature—Protective effects of endogenous and exogenous estrogen exposure in 
female and male animals during chronic hypoxia exposure have been demonstrated by 
multiple research groups (92, 115, 208, 335, 473, 474). Specifically, E2 administration has 
been shown to oppose hemodynamic alterations and pulmonary vascular remodeling in HPH 
both by attenuating hypoxia-induced upregulation of pro-angiogenic/pro-proliferative factors 
such as ET-1 (92), erythropoietin (296), and ERK1/2 (208) and promoting antiproliferative 
factors including the cell cycle inhibitor p27Kip1 (208, 474) and the autophagy marker LC3-
B (208).
Several studies have focused on identifying the role of ER signaling and activation in the 
pulmonary vasculature during HPH. Lahm et al. found that E2 attenuates HPH in an ER-
dependent manner, and that E2 exerts antiproliferative effects on hypoxic, but not normoxic, 
PAECs (208). In a study by Frump et al., a microarray analysis of HPH rat lungs treated with 
E2 or E2 plus the ER-antagonist ICI182,780 revealed that E2 regulates several genes that 
mediate proliferative and inflammatory processes during hypoxia and that these processes 
are dependent on ER (112). This method also revealed new ER targets in HPH including the 
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bone morphogenic protein antagonist gremlin 1, which was upregulated in hypoxia but 
reduced by E2 treatment (112). Other studies sought to identify the relative importance of 
each ER subtype in protecting the pulmonary vasculature during HPH. These studies 
revealed that both ERα and ERβ play a role in E2-mediated protection during HPH as 
blockade of either receptor eliminates E2’s inhibitory effects on PA muscularization and 
ERK1/2 activation in hypoxic PAECs (208). However, multiple lines of evidence suggest 
that ERβ-mediated signaling may be more vital for E2-mediated protection in HPH. For 
example, chronic hypoxia upregulates ERβ but not ERα in both rat and human PAECs (115, 
208). This occurs in a hypoxia-inducible factor 1α (HIF-1α)-dependent manner. ERβ 
activation, in turn, induces expression of the HIF inhibitor prolyl hydroxylase 2 (PHD2). 
Esr2 knockout mice display increased hypoxia-induced PA muscularization compared with 
wild-type or Esr1 knockout mice when treated with E2 during chronic hypoxia (115). ERβ 
and PHD2 therefore constitute a negative feedback loop that limits hypoxia-induced HIF-1α 
signaling and pulmonary vascular remodeling (115).
E2 supplementation is protective against pulmonary remodeling in MCT-PH. Farhat and 
colleagues demonstrated that E2 supplementation in male rats reduces PA remodeling 4 
weeks after MCT administration (99). A study by Yuan et al. in ovariectomized female rats 
demonstrated that E2 administration reduced pulmonary vascular muscularization and 
reduced total pulmonary resistance after MCT injection (483). Protective effects of E2 in the 
pulmonary vasculature were associated with suppressed macrophage infiltration in the 
pulmonary vasculature, as well as increased lung NO and prostacyclin levels, and reduced 
ET-1 expression. The authors also demonstrated that MCT administration reduced plasma 
E2 levels and reduced aromatase expression in the lung tissue. In contrast, the E2-
metabolizing enzymes CYP1A1 and CYP1B1 were upregulated in lung tissue. The authors 
suggested that MCT administration elicits an estrogen-deficient state. However, studies in 
PAH patients suggest a more complicated picture: while decreased E2 levels indeed have 
been reported in premenopausal women with PAH (482), another study demonstrated 
increased E2 levels in postmenopausal PAH patients (19), suggesting that E2 levels in PAH 
may be age dependent.
Two studies investigated the role of ERs in MCT-PH. A study by Umar et al. demonstrated 
that E2 administration attenuates MCT-induced PH and prevents disease progression to RV 
failure and death in male rats (432). In that study, E2 administration reduced PA 
muscularization, reduced lung inflammation and fibrosis, and induced pulmonary neoan-
giogenesis. Most impressively, these results were shown in a rescue model, in which the rats 
received E2 supplementation after PH was established. E2’s protective effects were 
mediated by ERβ signaling, as coadministration of an ERβ antagonist removed E2-mediated 
protection, while treatment with the ERβ agonist DPN recapitulated E2’s effects (432). 
Another study, however, suggested that the protective effects of E2 in this model are not 
mediated solely by ERβ. Here, chronic treatment with the GPR30 agonist G1 after MCT 
exposure was also able to ameliorate the PH phenotype (5). Specifically, G1 treatment was 
associated with decreased MCT-induced pulmonary vascular remodeling, decreased 
pulmonary fibrosis, and higher levels of eNOS protein in the pulmonary vasculature 
compared with vehicle treated rats.
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Several recent studies interrogated E2 effects on vascular remodeling and disease 
progression in the SuHx-PH model. SuHx-PH in rats is associated with reduced circulating 
E2 levels in female rats (114), similar to what has been described in MCT-PH (482). 
Ovariectomy-induced E2 depletion increased RVSP, whereas pulmonary vascular 
remodeling was not affected. E2 supplementation in ovariectomized female SuHx-PH rats, 
on the other hand, reduced RVSP and PA muscularization compared with ovariectomized 
SuHx-PH females and even intact SuHx-PH females. This suggests that E2 repletion in 
ovariectomized SuHx-PH females creates “super responders”, a phenomenon whose 
underlying mechanisms require further study. In the same study, male SuHx-PH rats were 
implanted with subcutaneous E2 pellets to elevate circulating E2 levels to those of female 
rats, but E2, while attenuating right ventricular hypertrophy (RVH) and rescuing CI to 
control levels, did not attenuate RVSP increases or prevent PA vascular remodeling (114). In 
a separate study, the same group employed the SuHx-PH rat model to examine the 
interaction between PH and exercise tolerance (213). In this experiment, ovariectomy 
worsened increases in RVSP (but not PA remodeling), and E2 supplementation in 
ovariectomized rats decreased PA pressures and reduced the abundance of fully 
muscularized vessels in the pulmonary vasculature. More critically, E2 supplementation was 
associated with a significant reduction in postexercise total pulmonary resistance (a 
surrogate for PVR (203)), indicating superior performance of the E2-supplemented 
pulmonary vasculature after strenuous exercise. Liu et al. examined the effect of E2 
supplementation on pulmonary hemodynamics in ovariectomized females in the SuHx-PH 
mouse model and found that E2 decreased PA elastance (a marker of RV afterload) and 
increased PA global compliance and transpulmonary vascular efficiency (defined as the ratio 
of cardiac output to total hydraulic power over the cardiac cycle) (232, 234, 235). 
Structurally, the authors demonstrated that E2 supplementation rescued SuHx-induced 
increases in PA wall thickness and collagen content. One curiosity is that Liu et al. did not 
find medial hypertrophy in the distal pulmonary arterioles as a result of SuHx-PH, likely 
because mice show a less robust response to this treatment than rats (446). Taken together, 
the results from the SuHx-PH studies suggest that E2, while being able to attenuate PA 
pressure increases and remodeling, has somewhat less-consistent effects on the PA than in 
the traditional PAH models such as HPH and MCT-PH (with the exception of E2 repletion in 
ovariectomized females, which dramatically rescues the PH phenotype). This is in stark 
contrast to E2’s profound RV effects in this model, which will be discussed further below. 
One important caveat is that sugen administration has been shown to upregulate both 
aromatase and CYP1A1 in rat lung tissue, indicating that pulmonary estrogen metabolism 
may be changed in this model of PAH (70). How these changes correlate with estrogen 
signaling in human PAH is currently under investigation.
Animal Studies Identifying Estrogen as a Disease Mediator in the Pulmonary 
Vasculature—Not all studies have demonstrated a protective effect of estrogen in the 
pulmonary vasculature. In fact, estrogen has been shown to promote PH development in 
several transgenic mouse models of PH—SERT+ mice (462), BMPR2−/− mice (51), and 
S100A4/Mts1 overexpressing mice (72). For example, female mice overexpressing the 
serotonin transporter (SERT+) develop severe PH when exposed to hypoxia, an effect not 
seen after ovariectomy. Additionally, exogenous E2 administration restores PH susceptibility 
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after ovariectomy in SERT+ females and induces proliferation in cultured human PASMCs 
in a manner dependent on de novo serotonin synthesis and activation of the serotonin 
receptor 5HTB (1B) (462). A latter study by the same research group demonstrated that the 
PH phenotype of SERT+ mice could be ameliorated by treatment with the ERα inhibitor 
MPP, which eliminated the proliferative pulmonary vascular phenotype while increasing 
expression of BMPR2 in the lungs of SERT+ mice (469).
Heritable PAH in humans is associated with mutations in the TGFβ superfamily receptor 
BMPR2 (62), and BMPR2 knockout mice spontaneously develop a mild form of PH (160, 
458). Recently, Chen et al. demonstrated that the PH phenotype and the occurrence of 
muscularized pulmonary arterioles were reduced by estrogen inhibition (with fulvestrant, 
anastrozole, or tamoxifen) in female BMPR2 mutants (51). Interestingly, when BMPR 
mutants were crossed with Esr1 or Esr2 knockout mice, loss of Esr1 reduced the rate of total 
pulmonary vessel occlusion while knockout of Esr2 completely eliminated vessel occlusion. 
This implies that ERβ signaling mediates the pathologic effects of estrogen in this model. 
The authors also linked estrogen signaling and Esr2 to the occurrence of metabolic defects 
such as oxidized lipid formation and insulin resistance as well as decreased abundance of the 
metabolic modulators peroxisome proliferator-activated receptor-γ and CD36.
In mice overexpressing the calcium-binding protein S100A4/Mts1, E2 administration further 
upregulated the expression of S100A4/Mts1 in PASMCs (72). This effect was associated 
with increased activation of S100A4’s receptor RAGE (receptor for advanced glycosylation 
end products) and a proliferative PASMC phenotype, leading to occlusive lesions in the 
pulmonary vasculature. There is convincing evidence that RAGE overexpression by PASMC 
contributes to PAH in humans, and RAGE inhibitors are effective in treating both MCT-PH 
and SuHx-PH in rats (270). Effects of endogenous and exogenous estrogens on mediating 
RAGE-induced SMC proliferation remain under investigation.
In another study of detrimental pulmonary estrogen signaling, Mair et al. showed that 
aromatase inhibition attenuated disease progression in both a mouse HPH model and a rat 
SuHx-PH model, but only in female animals (248). In both disease models, the aromatase 
inhibitor anastrozole decreased pulmonary vascular remodeling in a dose-dependent manner 
in females. Anastrozole also rescued PH-mediated decreases in BMPR2 protein levels in the 
lungs of female animals. Interestingly, this study showed that SuHx treatment increases the 
level of endogenous circulating estrogens in female rats, contrary to studies from other 
research groups (114). Mair et al. also demonstrated that E2 can increase proliferation and 
inhibit BMPR2 signaling in PASMCs from healthy controls (249).
In summary, animal studies examining estrogen signaling in the pulmonary vasculature 
during PH have produced conflicting and paradoxical results (Table 5). Exogenous E2 
administration improves PH outcomes and limits pulmonary vascular remodeling in HPH 
(92, 115, 208, 296, 335, 474), MCT-PH (99, 432, 483), and SuHx-PH (114, 213, 232, 234). 
On the other hand, attenuation of estrogen signaling by aromatase inhibition or ER 
antagonists appears to be protective in the HPH, SuHx-PH, and BMPR2 mutation models of 
disease in female rodents (248). Transgenic mouse models of PH have also identified 
estrogen as a necessary cofactor and mediator of specific disease pathways that contribute to 
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pulmonary vascular remodeling (51, 72, 462). Differences in model species (mouse vs rat), 
animal age, or estrogen source (endogenous vs. exogenous) between studies may contribute 
to these conflicting results. Dosing strategies for estrogen or its inhibitors need to be taken 
into consideration. This is of particular importance, as E2 clearly can exhibit dose-dependent 
effects and since ER inhibitors can also be partial agonists (109, 263). Tissue- or cell-type-
specific effects of estrogen or its inhibitors can be pronounced and induce variability as well. 
Furthermore, the timing of estrogen administration or inhibition relative to the onset and 
progression of PH may be an important factor. Lastly, confounders such as diurnal 
variations, estrogen coexposure in animal feeds, and even the gender of the animal handler 
need to be considered (383). More research into estrogen signaling in the lung considering 
these modifiers is required to parse the differential and contradictory effects shown here.
Estrogen Metabolites in Pulmonary Hypertension—Several estrogen metabolites 
have been identified as disease modifiers in PAH and may explain some of the divergent and 
paradoxical effects of estrogen signaling in disease models. 2-ME2, a nonestrogenic 
metabolite of E2, has been shown to be protective in several models of PH. Tofovic et al. 
were the first to demonstrate that 2-ME2 administration attenuates MCT-PH in male rats 
(420). 2-ME2’s protective effects were further characterized in several studies in which this 
metabolite attenuated MCT-PH in both male and female rats (418, 421) as well as in a model 
of bleomycin-induced PH and fibrosis (using ovariectomized female rats (422)). The 
synthetic analogue of 2-ME2, 2-ethoxyestradiol, exerts similar antimitogenic effects in the 
pulmonary vasculature and attenuates MCT-PH (423). 2-ME2 exerts strong antimitotic 
effects in ECs and inhibits ET-1 and MAPK activity even more acutely than E2 (81, 84). It 
has also been shown to inhibit systemic vascular remodeling by downregulating Akt and 
ERK1/2 activation, while upregulating cyclooxygenase-2 and the cell cycle inhibitor p27 
(22). As 2-ME2 can be synthesized from circulating E2 by ECs and SMCs (82,485), it is 
possible that the protective effects of E2 are mediated at least in part by conversion to 2-
ME2. Indeed, E2 does not inhibit proliferation of SMCs collected from Comt knockout mice 
(484), which do not express the necessary enzyme for formation of methoxyestradiol 
metabolites (2-ME2 and/or 4-ME2), indicating that synthesis of 2-ME2 may be important 
for estrogen effects in some cell types. Furthermore, pathological conditions such as hypoxia 
and inflammation (both factors in PAH/PH etiology and progression) have been shown to 
decrease activity of CYP1A1 (one of the enzymes responsible for E2 conversion to the 2-
ME2 precursor 2-OHE2). Since this would result in limiting the 2-hydroxylation pathway 
(107, 407) and 2-ME2 production, it is conceivable that decreased 2-ME2 production could 
contribute to hypoxia- or inflammation-mediated PH. However, at least in hypoxia, this 
conversion is not necessary for E2 to attenuate PH development (208). In addition, selective 
ER agonists recapitulate some or all of the effects of E2 administration in many PH models, 
indicating that 2-ME2 is not the sole mediator of E2’s salutary effects. Lastly, at least in one 
study, 2-ME2 administration exhibited only modest effects (101).
In contrast to the antiproliferative effects of 2-ME2, the estrogen metabolite 16α-OHE1 has 
been identified as a contributor to PAH development. An association among BMPR2 genetic 
status, 16α-OHE1 production, and PAH development was first identified by West et al. (457) 
and Austin et al. (12). The authors found that a single-nucleotide polymorphism (SNP) in 
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CYP1B1 (one of the enzymes responsible for production of 16α-OHE1 as well as 2-OHE2; 
Figure 3) results in lower CYP1B1 activity and a lower urinary 2-OHE2/16α-OHE1 ratio in 
BMPR2 carriers that developed PAH as compared to nonaffected carriers. The data from 
animal models of PH supports the theory that increased 16α-OHE1 activity promotes PH. 
White et al. demonstrated that pulmonary CYP1B1 levels are increased by both hypoxia and 
SuHx-PH, that Cyplbl knockout mice are resistant to HPH, and that administration of the 
CYP1B1 inhibitor 2,3′,4,5′-tetramethoxystilbene (TMS) attenuates PH resulting from both 
hypoxia or SuHx (463). While it is unclear why White et al. found increased CYP1B1 
expression as compared to the decreased activity noted by West and Austin, both groups 
implicated 16α-OHE1 in PAH development. In vitro experiments by White et al. confirmed 
that 16α-OHE1 provoked proliferation in human PASMCs, particularly PASMCs collected 
from PAH patients. Finally, the authors demonstrated that 16α-OHE1 injection could elicit a 
PH phenotype in mice (463). Other models of PH have also been shown to exhibit 
upregulated CYP1B1 expression in the lung, including SERT+ mice, anorexigen-induced 
PH female mice, and female MCT-PH rats (71, 464, 483), identifying altered CYP1B1 
activity as a disease mediator in experimental PH. Interestingly, administering 16α-OHE1 to 
BMPR2 mutant mice doubles the penetrance of PH (101) and disrupts cellular metabolism 
through upregulation of miRNA-29 (52). Both CYP1B1 and 16α-OHE1 are attractive 
therapeutic targets due to a conserved expression pattern between humans and animal 
models, and the dramatic effect of inhibition in animal models.
Taken together, while there is a discrepancy between animal and human studies with regard 
to CYP1B1 activity/expression, there is robust evidence that 16α-OHE1 promotes a PAH 
phenotype in vivo and in vitro. 2-ME2, on the other hand, can promote adaptive processes. 
These studies have led to a paradigm of “bad” and “good” estrogen metabolites and altered 
estrogen metabolism in PAH.
Human Studies—Despite the epidemiologic observations reviewed above, until recently 
few clinical studies have explored the role of estrogens in PAH pathogenesis, risk, and 
outcomes. Higher levels of circulating E2 have been found in both men and postmenopausal 
women with PAH as compared to age- and body mass index-matched healthy controls (19, 
441, 471). In a study comparing 23 men with WHO Group 1 PAH (including idiopathic 
PAH, heritable PAH, and CTD-associated PAH) and 67 sex-, age-, and weight-matched 
healthy controls, higher E2 levels were associated with the risk of PAH, such that a 1-unit 
increase in E2 increased the risk of PAH 50-fold, and also shorter 6MWD in PAH cases 
(441). These results were replicated in a larger prospective cohort of 95 men with idiopathic 
PAH from China; in this study, higher E2 levels were also independently associated with 
death in PAH patients (471). In 112 postmenopausal women ≥ age 55 with idiopathic PAH, 
heritable PAH, or CTD-associated PAH, PAH cases had higher circulating E2 levels as 
compared to matched controls, and higher E2 levels were associated with shorter 6MWD 
(each per unit increase was associated with a 32-m decrement in 6MWD, the minimally 
important difference for the 6MWD in PAH), higher RAP, and worse functional class (19, 
259). In postmenopausal women with limited cutaneous SSc, the use of HT (most 
commonly combination estrogen/progesterone) after menopause decreased the risk of the 
development of echocardiographic PH, although there were no differences in single 
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measurements of E2 levels between those who did and did not develop PH (30). A second 
study demonstrated that menopause was an independent risk factor for the development of 
PH in SSc (363). There have been no published studies that measure circulating estrogens in 
premenopausal women with PAH, perhaps because it is difficult to control for the impact of 
menstrual cycle variation on these levels.
As mentioned above, 2-OHE2 and 16α-OHE1 have different effects on inflammation and 
mitogenesis and have previously been implicated in oncogenesis and vascular metastatic 
invasion (83). Austin and colleagues discovered alterations in E2 metabolism in heritable 
PAH and demon-strated that a CYP1B1 polymorphism increased the risk of PAH penetrance 
in women with BMPR2 mutations, but not in carrier men (12). In addition, the presence of 
the CYP1B1 mutation in PAH patients was associated with lower urinary 2-OHE2/16α-
OHE1 ratios (12, 13, 463). In a small study, 10 men with heritable PAH had a higher 
proportion of the mitogenic metabolite (16α-OHE1) compared to the anti-inflammatory/
antiproliferative metabolite (2-OHE2) as compared to healthy controls (101). This same 
group described direct ERα binding to the BMPR2 promoter, leading to reduced BMPR2 
gene expression in females, and demonstrated that 16α-OHE1 promotes the development of 
heritable PAH via upregulation of microRNA-29, which plays a key role in cellular 
energetics and metabolism (13, 52). Interestingly, increased expression of 16α-OHE1 has 
been demonstrated in pulmonary arterioles from the explanted or autopsied lungs of PAH 
patients as compared to non-PAH lungs (463). These important connections among sex, E2 
metabolite balance, altered BMPR2 expression, and effects on cellular metabolism may 
underpin the female predominance of heritable (and perhaps idiopathic) PAH. The role of 
these pathways in men with PAH and nonheritable disease has not been elucidated.
The Pulmonary Vascular Complications of Liver Disease Cohort enrolled patients with 
chronic liver disease and then performed a case-control study to determine genetic risk 
factors for portopulmonary hypertension in 15 candidate genes of interest (340). 
Polymorphisms in ESR1 and CYP19A1 (which encodes for aromatase) were associated with 
altered risk of developing portopulmonary hypertension. Moreover, biologic activity of the 
aromatase variants was suggested by a correlation between increased circulating E2 levels 
and genotype (340). Both ERα and aromatase are present in human lungs. Specifically, 
increased ERα expression has been demonstrated predominantly in PASMCs from 
explanted lungs of women with PAH as compared to control lungs (469). Peripheral 
aromatase activity (which accounts for most of the estrogen production in postmenopausal 
women and men) is present in SMCs of the small muscular PAs of explanted lungs from 
women with PAH. Complementary animal experiments implicate this enzyme in pulmonary 
vascular disease pathogenesis (248, 469).
A recently completed randomized, double-blind, and placebo-controlled trial demonstrated a 
significant reduction in circulating E2 levels with anastrozole treatment versus placebo, but 
no effect on echocardiographic RV measures at 12 weeks in 18 men and postmenopausal 
women with Group 1 PAH (193). Other hormone levels (specifically testosterone, 
progesterone, and DHEA-S) were not affected. Active treatment also resulted in an 
improvement in 6MWD (+26 m) compared to placebo (−12 m) (median % change from 
baseline was +8% versus −2%, respec-tively [p = 0.042]), and there were no adverse events. 
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This small pilot study demonstrates the feasibility of hormonal manipulation as a treatment 
strategy in PAH. A longer, larger Phase II multicenter, randomized, double-blind, and 
placebo-controlled trial of anastrozole is ongoing (NCT03229499) in men and 
postmenopausal women with WHO Group 1 PAH. Tamoxifen, a selective ER modulator, is 
also being studied in a single-center, randomized, double-blind, and placebo-controlled 
Phase II trial in subjects with idiopathic, heritable, drug- or toxin-induced, or CTD-
associated PAH (NCT03528902).
Estrogens and RV function
Cell Culture and Animal Studies—Previous studies in the LV demonstrated that 
estrogen signaling promotes the maintenance of myocardial metabolism and inhibits 
inflammation, fibrosis, and apoptosis in response to acute or chronic injuries such as 
pressure overload (104, 173, 216, 230, 452, 453). Of note, cardioprotective effects of the 
PDE5 inhibitor sildenafil in two animal models of left ventricular dysfunction are estrogen 
dependent (354). Healthy women exhibit superior RV systolic function compared to men, a 
relationship that correlates with E2 levels and that persists among patients with PAH (192, 
196, 444). These observations indicate that E2 may exert direct RV-protective effects during 
PAH/PH, altering disease progression independent of its effects in the pulmonary 
vasculature. Indeed, several animal studies have confirmed this notion.
E2 supplementation of male rats during hypoxia reduced RVSP and RV hypertrophy, while 
increasing cardiac output (208). Cotreatment with the ERα antagonist MPP increased RV 
hypertrophy and reduced cardiac output to levels seen in untreated hypoxic animals. 
Nonselective (dual) ER blockade was required to attenuate other E2-mediated effects inthe 
RV such as ERK1/2 inhibition. These results indicate that estrogen signaling in the 
chronically hypoxic RV may involve multiple ERs, which initiate both unique and redundant 
downstream signaling. However, it should be noted that these effects on RV structure, 
function, and signaling may be secondary to the lower RVSP and PA remodeling noted with 
E2 treatment.
Several studies found that E2 mediates RV-protective effects in MCT-PH. Umar et al. treated 
male rats with E2, ERα agonist (PPT), or ERβ agonist (DPN) after MCT injection (432). E2 
supplementation improved RVEF and decreased RV hypertrophy. E2 also promoted 
neoangiogenesis in the RV, thereby increasing vessel density. This observation is critical as 
vessel rarefaction and impaired angiogenesis in the RV is suggested to play a major role in 
RV failure during PH (reviewed in Ref. 113). Protective effects of E2 were recapitulated by 
DPN, suggesting that ERβ is involved in mediating its cardioprotective effects. Another 
study by the same group demonstrated similar effects of E2 administration after MCT 
injection of aged (12–14 months) female ApoE knockout mice, indicating that estrogen may 
be vital in attenuating PH in aged subjects with a disrupted reproductive cycle (433). 
Nadadur et al. demonstrated that E2 treatment reduces RV fibrosis after MCT administration 
(298). Effects of E2 in this study were largely recapitulated by the ERβ agonist DPN, similar 
to the effects noted by Umar et al. In recent studies from Alencar et al., activation of GPR30 
with the GPR30 agonist G1 attenuated the effects of MCT in a rat model (5, 6), indicating 
that nongenomic estrogen signaling may also be critical to RV protection. As in the studies 
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performed in HPH models, E2 or ER agonist also affected RVSP and PA remodeling in all 
these studies, making it difficult to dissect whether ER signaling exerts direct effects on the 
RV or whether RV structure and function improved as a result of lower RV afterload. 
However, Nadadur et al. demonstrated that E2 administration decreases fibrosis markers in 
cultured cardiac fibroblasts (298), indicating that this cell population is a direct target of E2.
More recent studies evaluated E2’s effects in angiopro-liferative PH. Using the SuHx-PH 
animal model, multiple groups have identified robust RV-protective effects of E2 (114, 213, 
232-235). In one study, both endogenous (intact females) and exogenous (E2 repletion in 
ovariectomized rats) estrogens improve cardiac output and exercise capacity, and attenuate 
SuHx-induced increases in expression of pro-inflammatory and proapoptotic mediators as 
well as markers of mitochondrial dysfunction and oxidative stress. In addition, E2 increased 
abundance of the pro-angiogenic and pro-contractile peptide apelin (114). SuHx-PH also 
decreases expression of ERα in the RV, while E2 repletion increased ERα abundance. ERβ, 
GPR30, and aromatase, on the other hand, were not altered. E2 supplementation was also 
RV protective in male SuHx-PH rats, and administration of an ERα agonist replicated these 
effects. ERβ agonist treatment, on the other hand, was less efficacious, suggesting that ERα 
is primarily mediating E2’s RV-protective effects. A later study demonstrated that E2 
abrogates decreases in RV function in SuHx-PH induced by an acute exercise challenge, an 
effect that was accompanied by increased RV antiapoptotic signaling, eNOS activation, and 
signs of improved autophagic flux. Similar to the results from Nadadur et al., Lahm et al. 
noted that E2 inhibited RV fibrosis (213). Concomitant inhibitory effects on RVSP and PA 
remodeling in both studies precluded determining whether E2’s effects on the RV were 
direct or indirect. This question was elegantly addressed by Liu et al. (233, 234). Using a 
SuHx-PH mouse model with E2 repletion in ovariectomized females, these authors 
demonstrated that E2-mediated cardioprotective effects in this model were both direct (by 
increasing RV contractile function) and indirect (by decreasing collagen accumulation and 
increasing compliance in the proximal PA). These authors also examined mitochondrial 
function in the RV and found that E2 supplementation improved both mitochondrial density 
and respiratory function compared with placebo-treated animals (233). Finally, this group 
demonstrated that E2 treatment preserves PA compliance after SuHx treatment, which 
reduces the pulsatile load on the RV, leading to improved RV function and improved 
ventricular-vascular coupling (232, 235).
In summary, data from multiple animal models clearly demonstrate that E2 improves RV 
function, structure, and biochemical processes in PH (Table 5). Interestingly, even in animal 
models of E2-mediated pulmonary vascular prolifer-ation, RV-protective effects such as 
reduced RV hypertrophy are often observed (419, 462). We are now beginning to understand 
the mechanisms of estrogenic signaling in the RV. All three ERs have been implicated in 
mediating RV protection (albeit with differences between model system), but their individual 
contributions and importance must be studied in more detail. In addition, PA-independent 
effects of estrogenic signaling (e.g., using a PAB model) need to be studied in more detail.
Human Studies—A key and unanswered question in human PAH is whether estrogens 
have a direct role in RV adaptation, which may serve to explain why more women than men 
develop PAH but have preserved RV function and better survival (Table 2). While such a role 
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of estrogens is clearly suggested by the animal studies reviewed above, there are no human 
studies directly linking circulating estrogens to RV morphology in PAH, and the only 
observational data to date has been performed in an epidemiologic cohort without clinical 
cardiovascular disease (the MESA-RV Study). In postmenopausal women from MESA-RV 
using HT, higher E2 levels were associated with higher RVEF and lower RV end-systolic 
volume, but this relationship was not seen in non-HT users or men (444). The association 
seen in HT users only may be explained by greater E2 levels, a higher degree of variation in 
E2, altered or unmeasured estrogen metabolites, or protein/receptor interactions. Exogenous 
HT may lead to upregulated ER tissue expression and altered E2 sensitivity (76). High E2 
states have been associated with heart neovascularization, and human ventricular 
myocardium contains functional ERs, which may result in adaptive remodeling and better 
RV systolic function (174, 272).
Cytochrome P450 enzymes are preferentially expressed in the RV (as compared to the LV) 
in humans (414). A follow-up study in MESA-RV demonstrated that genetic variation in 
CYP1B1 was independently associated with increased RVEF in postmenopausal women 
(443). This polymorphism is tightly linked to the variant that increased the risk of PAH in 
BMPR2 carriers (12) described above as well as variants tied to angioinvasion in cancer (75, 
190, 312, 456). There were no associations noted in other candidate genes important in 
estrogen signaling and metabolism including ESR1 or ESR2 or CYP19A1. Urinary estrogen 
metabolites were also measured and were associated with RVEF but did not mediate the 
CYP1B1 SNP-RVEF relationship. Interestingly, the CYP1B1 polymorphism-RVEF 
association was strongest in black women, who have the highest female predominance in 
PAH. Activity and by-products of the cytochrome P450 subfamilies and E2 metabolite 
balance can be altered acutely during hypoxia, inflammation, with the onset of vascular 
disease, and with daily dietary changes (184, 275). This suggests that the impact of these 
metabolites on the cardiopulmonary unit is complex and may vary depending on an 
individual’s race/ethnicity, age, hormonal milieu (endogenous and exogenous), and disease 
course. These observations lend support to the hypothesis that sex hormones and their 
genotypes may have pleiotropic effects on the pulmonary circulation and RV and give rise to 
unique sex-based phenotypes in PAH. Given the profound effects of E2 on RV function, the 
two ongoing trials of E2 reduction as a treatment strategy in PAH (anastrozole, 
NCT03229499 and tamoxifen, NCT03528902) are incorporating echocardiographic 
measures of RV function as safety and efficacy end points in subjects with PAH.
In summary, data from animal and human studies confirm that estrogens are a clinically 
relevant modifier of RV function in PAH/PH (Tables 2 and 5). Elucidating the exact role of 
estrogenic signaling during RV adaptation to increased afterload may allow for the 
development of targeted therapies that improve cardiac adaptation in PAH/PH while 
avoiding potential off-target effects in the pulmonary vasculature.
Testosterone in PH
Testosterone Signaling and Metabolism
Testosterone and its metabolite DHT are ligands for the androgen receptor (AR). DHT is a 
far more potent androgen than testosterone (approximately 10 times) due to its relatively 
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higher binding affinity and slower dissociation rate from the AR (134). Like other steroid 
hormones, androgens signal primarily through a genomic pathway to alter gene expression. 
Ligand binding initiates AR dimerization, nuclear localization, binding to androgen response 
elements in the DNA, and transcriptional modification of target genes. Nuclear cofactors 
(coactivators/corepressors), chromatinmodifying enzymes, and posttranslational 
modification of the AR all play a role in modifying androgen signaling in target cells (261). 
Like estrogens, androgens may also exert effects through a nongenomic signaling pathway 
acting through cytoplasmic or membrane-bound ARs. By doing so, testos-terone or DHT 
can rapidly initiate cell signaling pathways including rapid calcium influx (128), MAPK 
signaling (320), PI3K/AKT activation (121), cytoskeletal reorganization (311), or apoptosis 
(65, 413). Androgen signaling is vital for development and function of the male reproductive 
tract and development of secondary sex characteristics in males, but also plays a critical role 
in the cardiovascular system (85). Particularly relevant to PAH/PH, the AR is expressed in 
vascular SMCs, EC, lung tissue, and both atrial and ventricular cardiomyocytes (85, 237, 
238, 276). Circulating testosterone levels fall in aged males (Table 4), and animal models 
indicate that this effect may be compounded by a reduced androgen sensitivity of the 
vasculature (94). Isolated coronary arteries from aged male rats display a muted response to 
testosterone in vitro (94), while AR expression in heart tissue is dependent on circulating 
testosterone levels (124). Careful study of androgen signaling in the cardiovascular systems 
of men and women in the context of aging, estrogen/androgen balance, and pulmonary 
vascular disease may provide data relevant to the sexually dimorphic progression of PAH.
As discussed in the hormone synthesis section, circulating testosterone may be converted to 
E2 by aromatase in peripheral tissues. It is therefore conceivable that any experimental 
effects of endogenous or exogenous testosterone administration could be mediated by 
estrogen signaling in target tissues after aromatization. To this point, the ratio of circulating 
E2/testosterone has been associated with cardiovascular disease risk in epidemiologic 
studies (68, 489). Careful monitoring of hormone levels and/or administration of 
nonaromatizable DHT is required in experimental systems to accurately identify the effect of 
androgens in PH.
Testosterone in the Pulmonary Vasculature
Cell Culture and Animal Studies—Studies in isolated human (343, 382) and rat (95) 
pulmonary vessels demonstrated that testosterone is a powerful vasodilator in this vascular 
bed. While testosterone elicits vasodilation in tissue collected from either sex, the 
vasodilatory response appears to be greater in male tissue (95, 343). Acute testosterone-
induced vasodilation is nongenomically mediated by antagonistic effects on voltage-gated 
calcium channels and a subsequent reduction in calcium influx into SMCs (139, 181, 364). 
While the acute vasodilation response to testosterone involves vascular SMCs, androgens 
also act through genomic signaling pathways to promote NO synthesis in cultured systemic 
ECs (123, 280). Both classical AR signaling and activation of ER signaling after 
aromatization have been implicated in this process (reviewed in Ref. 241), and the 
pulmonary vasculature of male eNOS knockout mice exhibits increased muscularization 
compared to female knockouts (278). While testosterone-induced vasodilation would be 
expected to protect the male lung against incipient PAH/PH, effects of testosterone on other 
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clinically relevant processes in PAH (e.g., proliferation, metabolism, and inflammation) are 
largely unknown. In particular, the role of androgens in pulmonary vascular remodeling 
during PAH has not been studied. In cultured systemic vascular SMCs and ECs, androgenic 
signaling promotes proliferation (117, 384). In addition, androgen signaling opposes EC 
dysfunction, oxidative stress, and inflammation (55). These data suggest that testosterone 
may exert biologically relevant effects in the pulmonary vasculature (Table 6) as well and 
provide a rationale to study these pathways in more detail.
Human Studies—Testosterone deficiency has been demonstrated in a number of chronic 
diseases (341, 424). Two studies have measured circulating testosterone levels in men with 
PAH with discordant results. In a cohort of 95 Chinese men with idiopathic PAH, 
testosterone deficiency was found in 54% of PAH patients as compared to matched healthy 
controls (471). In 23 men with idiopathic, heritable, or CTD-associated PAH, there were no 
differences between total and bioavailable testosterone levels in PAH cases as compared to 
matched controls, perhaps due to the smaller sample size or greater variation in PAH 
diagnoses and race/ethnicity in this study (441). In both studies, the findings with circulating 
E2 levels (higher levels associated with PAH and more severe disease) were more robust and 
drove associations between greater E2/testosterone ratios and the risk of PAH. Total 
testosterone levels were not associated with disease severity in either study nor survival in 
the Chinese cohort. Lower levels of total testosterone and bioavailable testosterone increased 
the odds of PAH threefold in a study of postmenopausal women with Group 1 PH, but there 
were no consistent associations observed between lower testosterone (or bioavailable 
testosterone) levels and markers of PAH severity (19). Taken together, testosterone levels 
may be lower in PAH than in health (as has been described for many chronic diseases), but 
currently available human studies do not suggest that lower circulating testosterone levels 
are associated with worse pulmonary vascular disease.
Testosterone in the RV
Cell Culture and Animal Studies—RV hypertrophy in response to increased PVR is a 
hallmark of PH. Androgens promote cardiomyocyte hypertrophy in vitro (256), in animal 
models (43), and in cases of anabolic steroid abuse (2). However, this effect has primarily 
been studied in the LV. Compounding this effect, cardiac hypertrophy significantly elevates 
expression of 5α-reductase, increasing conversion of testosterone to DHT and promoting a 
positive feedback loop of androgen signaling and hypertrophy (415). Two recent studies 
have examined the role of androgen signaling in cardiac hypertrophy resulting from pressure 
overload. Montalvo et al. showed that male mice exhibit more severe LV dilatation in 
response to transverse aortic constriction (TAC) compared with female or castrated animals, 
and that this effect was TGFβ dependent (284). Zwadlo et al. demonstrated that DHT 
appears to drive this phenotype as inhibition of 5α-reductase significantly reduced LV 
hypertrophy in male mice after TAC (491). While there are physiological differences 
between the left and right ventricle, animal studies focusing on the RV demonstrate a similar 
hypertrophic effect of androgens. Specifically, castrated male rats demonstrate RV 
hypertrophy when administered testosterone (286). Interestingly, the effects of testosterone 
on RV hypertrophy are additive to those of hypoxia, an effect not seen with other steroid 
hormones. In a PAB model of RV dysfunction, castrated male mice exhibit less RV 
Hester et al. Page 33













hypertrophy, while testosterone replacement after castration leads to increased levels of 
hypertrophy (154). In parallel, testosterone promotes RV fibrosis, whereas testosterone 
deprivation appears to improve survival. This indicates that testosterone may promote a 
maladaptive type of RV hypertrophy.
Human Studies—Testosterone increases the myocardial inflammatory response and 
promotes cardiac remodeling (200, 300). Epidemiologic studies have shown that left heart 
failure is characterized by testosterone deficiency and is associated with worse 
cardiovascular outcomes in men (199, 251). The role of androgens in cardiovascular health 
remains controversial, however, because of mixed results with testosterone supplementation 
in human studies (41, 102). In the same study from MESA-RV, which demonstrated that 
higher E2 levels were linked to higher RVEF in postmenopausal women HT users, 
bioavailable and total testosterone levels were associated with greater RV mass and larger 
RV volumes (including RV stroke volume) in men only and were independent of LV 
measures (444). It is unknown whether these associations may be adaptive or maladaptive in 
pulmonary vascular disease as this study was cross-sectional in nature and performed in a 
cohort without clinical cardiovascular disease. There were no relationships noted between 
circulating testosterone or bioavailable testosterone levels and echocardiographic RV 
structure or function or natriuretic peptide levels in postmenopausal women with Group 1 
PH; studies performed in men with PAH did not assess RV function (19).
In the follow-up genotype-RV phenotype study from MESA-RV, two polymorphisms in the 
AR gene were associated with RV end-diastolic volume and mass in men only and were 
dependent on circulating testosterone levels, indicating that these variants may have biologic 
relevance (443). ARs are present in human cardiomyocytes and stimulate hypertrophy with 
testosterone binding (256). Testosterone also directly regulates AR transcription during left 
ventricular hypertrophy in human hearts (415). AR interactions may lead to changes in RV 
morphology via both genomic and nongenomic effects that depend on the androgen, 
hormone concentration, cardiac receptor density, and sex of the individual.
Taken together, it appears that androgens may be protective in the pulmonary vasculature by 
promoting vasodilation, but detrimental to RV remodeling in the face of increased afterload 
(Tables 2 and 6). This hypothesis fits the clinical data in which men are less likely to develop 
PAH but display decreased survival rates compared with women. However, there is a paucity 
of mechanistic studies examining the role of androgen signaling in proliferative processes in 
the pulmonary vasculature. Studies from the systemic vasculature suggest that testosterone 
and androgenic signaling may promote PA wall cell homeostasis and also enhance 
proliferation, suggesting that pulmonary vascular effects of testosterone need to be studied in 
more detail. More mechanistic studies evaluating androgenic signaling in the RV are 
required as well.
Progesterone in PH
Progesterone Signaling and Metabolism
Progesterone is primarily synthesized by the ovarian corpus luteum during the menstrual 
cycle as well as by the placenta during pregnancy. Progesterone is one of the most critical 
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hormones during pregnancy, and many physio-logical changes of pregnancy are 
progesterone mediated (reviewed in Ref. 153). Progesterone signaling is necessary for 
differentiation and maintenance of female reproductive tissues including the uterine and 
mammary epithelium (133). Like other steroid hormones, progesterone signals through 
binds to a steroid receptor (progesterone receptor, PR) and subsequently modulates gene 
transcription as well as through nonclassical pathways, which include genomic and 
nongenomic signaling cascades (120). Cofactors including transcriptional activators/
repressors, chromatin-modifying enzymes, and posttranslational modification of the PR may 
alter progesterone signaling in target cells (133).
PR is expressed in ECs, including proliferative ECs and myofibroblasts found in plexiform 
lesions isolated from PAH patients (21,455). PR is also highly expressed in the systemic 
vasculature and in cardiac tissue, such as ECs and SMCs of the aorta, carotid and coronary 
arteries, and cardiomyocytes (172). Vascular expression of PR in the uterine vasculature 
varies according to the phase of the menstrual cycle and tends to decrease with age (217). It 
is possible that PR expression in other tissues demonstrates similar cyclicity. Interestingly, 
estrogen upregulates expression of the PR in cardiovascular tissue (186, 229), an effect that 
may be relevant to PAH disease progression.
In vitro culture of ECs revealed that PR activation suppresses cytokine production (122) and 
inhibits ET-1 synthesis (288). PR knockout mice demonstrate increased vascular medial 
hypertrophy and SMC proliferation after vascular injury, and isolated vascular SMCs from 
PR knockout mice are hyperproliferative in culture (188). These studies indicate that PR 
signaling might play a protective role by limiting the inflammatory, angiogenic, and 
proliferative phenotypes of PAH/PH; however, exogenous progesterone has also been shown 
to intensify vascular injury response in wild-type mice (188). Studies to clearly define the 
role of progesterone signaling in the pulmonary vasculature generally and in the context of 
PAH specifically are clearly needed.
Progesterone in the Pulmonary Vasculature and RV
Cell Culture and Animal Studies—Investigations of sex and gender differences in 
PAH/PH have focused on the role of estrogens, while remarkably few studies have examined 
the role of progesterone. This imbalance is surprising given that both hormones are much 
more abundant in women compared to men (Table 4).
Progesterone regulates proliferation of both ECs and SMCs (222, 223, 287, 438) and has 
been shown to be vasodilatory in pulmonary vessels isolated from both rats (95) and rabbits 
(226). While one study in humans found that oral progesterone supplementation opposed 
vasodilatory effects of estradiol (281), this study was not conducted in the pulmonary 
vasculature.
Tofovic et al. demonstrated that progesterone administration mitigates MCT-induced PH in 
rats (416). Specifically, progesterone supplementation in ovariectomized MCT-PH rats 
attenuated MCT-induced increases in RVSP, RV hypertrophy, PA remodeling, and mortality 
compared with untreated ovariectomized MCT-PH rats. Despite the encouraging results of 
this study, no data on the role of progesterone in animal models of PH has been published in 
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the subsequent decade. Further studies that mechanistically evaluate pulmonary vascular 
effects of progesterone as well as the interaction between progesterone and estradiol in the 
context of PAH/PH could generate new knowledge to expand our understanding of sex 
steroid signaling and sex/gender differences in this field.
Little is also known about the role of progesterone during PH-induced RV remodeling. 
Progesterone promotes cardiac hypertrophy in other contexts, implying that it may drive RV 
adaptation as well. Progesterone can induce cardiac protein synthesis (125) as well as 
initiate hypertrophy in isolated rat cardiomyocytes (57). Additionally, progesterone is the 
dominant hormone of pregnancy, a condition that results in transient cardiac hypertrophy. 
Progesterone promotes cardiac hypertrophy in vitro, and PR activation inhibits apoptosis in 
cultured rat cardiomyocytes (293). One intriguing hypothesis is that progesterone may 
promote “physiological” (or adaptive) cardiac hypertrophy (56, 57, 283, 472) rather than the 
maladaptive cardiac hypertrophy associated with severe PH. However, this hypothesis has 
yet to be tested in the context of PAH/PH. On the other hand, pregnant women with PAH are 
at a particular high risk for increased morbidity and mortality (153, 273, 400). Whether this 
is directly or indirectly linked to the increased progesterone levels of pregnancy is unknown. 
A better understanding of the cardiopulmonary effects of progesterone in health and disease 
is critical for understanding the mechanisms of adaptive and maladaptive changes in both 
pregnant and nonpregnant women with PAH.
Human Studies—While progesterone has known effects on the respiratory system, its 
impact on the cardiovascular system is less well understood (20, 77). Two studies (described 
above) measured progesterone levels in PAH patients (19, 471). In postmenopausal women, 
there were no differences in circulating progesterone levels in subjects with PAH as 
compared to matched controls and no associations between progesterone levels and disease 
severity in PAH subjects including RV function assessed by echocardiography (19). In the 
study of men with idiopathic PAH from China, lower progesterone levels increased the risk 
of PAH and were associated with worse functional class, shorter 6MWD, and more severe 
hemodynamic impairment (471). There was no association between progesterone levels and 
mortality in this study, and RV structure and function were not assessed. There have been no 
studies of circulating progesterone levels in premenopausal women with PAH, which may be 
more informative than in postmenopausal women, and no human studies to date of the 
relationship between progesterone and RV performance in PAH or in health.
Taken together, the limited body of literature on progesterone in PAH/PH demonstrates that 
this hormone may be beneficial in the pulmonary vasculature and possibly even in the RV 
(Tables 2 and 6). However, more studies of progesterone in PH are needed to more clearly 
define its role.
DHEA in PH
DHEA Signaling and Metabolism
Pregnenolone is the prohormone to progesterone and DHEA. DHEA and DHEA-S are 
precursors in the biosynthesis of androgens and metabolized directly to androstenedione, 
testosterone, and subsequently estrogens. DHEA and DHEA-S are produced predominantly 
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in the adrenal cortex and are the most abundant circulating endogenous steroids but wane 
with aging. The hormone has been shown to have direct genomic and nongenomic effects on 
vasculature as well as cardiomyocytes (254). DHEA binds directly to vascular endothelium 
to activate NO synthase and regulates ET-1 production, two key drivers in PAH pathobiology 
that are also major treatment targets (50, 236, 254, 301). When human systemic vein ECs 
are exposed to DHEA, inflammatory signaling is reduced (7, 451). DHEA has been shown 
to rescue cardiomyocyte hypertrophy induced by ET-1 (301) and to prevent myocardial 
fibrosis and contractile dysfunction through the restoration oxidative balance and 
downregulation of advanced glycation end products (AGEs) and its receptors, reducing 
tissue levels of collagen and fibronectin (9, 10).
DHEA in the Lung Vasculature
Cell Culture and Animal Studies—DHEA exposure at variable concentrations has been 
shown to induce phenotypic changes in human ECs in vitro (7, 23, 164, 221, 316, 451). 
Effects include enhanced eNOS expression, NO synthesis, and variable ET-1 secretion (50, 
164). Human PAECs actively metabolize DHEA, and treatment of PAECs from PAH 
patients decreases activation of STAT3 (277, 316), an important mediator of pulmonary 
vascular remodeling. DHEA appears to be consistently beneficial in experimental PH. 
Although these studies have been done in predominantly male animals, DHEA has been 
used as both a prevention and rescue strategy following exposure to hypoxia, altitude, MCT, 
MCT-pneumonectomy, and SuHx (8, 37, 88, 144, 159, 316). These studies and the 
mechanisms by which DHEA is proposed to prevent or reverse experimental PH as well as 
the effects on cardiomyocytes are summarized in Table 7.
Human Studies—In addition to high levels of circulating E2 in PAH, studies of both men 
and postmenopausal women have demonstrated significantly lower (50%) levels of DHEA-S 
(which is more stable in blood samples than DHEA) in PAH subjects as compared to age- 
and body mass index-matched controls (19, 441). In men with PAH, lower levels of DHEA-
S were associated with worse hemodynamics (higher RAP and higher PVR). There were 
more robust associations with disease severity in postmenopausal women (i.e., lower levels 
of DHEA-S were associated with worse 6MWD, functional class, hemodynamics, and worse 
RV function by echocar-diography) as well as an association with worse survival such that 
every unit decrease in DHEA-S was associated with a doubling in the risk of death (19). 
While DHEA is a prohormone of E2 and testosterone (and testosterone can be aromatized to 
E2), there were no strong correlations among hormone levels (DHEA-S, E2, and 
testosterone) and no evidence of effect modification among interrelated hormones, implying 
that DHEA may have a direct role in the development and progression of PAH and RV 
adaptation. A second study of unbiased metabolomic profiling demonstrated that DHEA-S 
and its metabolites were reduced in PAH patients compared to healthy controls and that 
lower circulating levels of DHEA-S were associated with mortality in PAH patients (337). In 
eight patients with PH related to chronic obstructive pulmonary disease, open-label 
treatment with 3 months of DHEA was associated with a significant increase in 6MWD and 
improvements in hemodynamics without adverse effects (90). These studies have led to the 
third randomized clinical trial of hormonal modulation as a treatment strategy in PAH; a 
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single-center, double-blind, and placebo-controlled crossover trial of DHEA 
supplementation in subjects with Group 1 PH is ongoing (NCT03648385).
DHEA and the RV
Animal Studies—Several studies have demonstrated a role for DHEA in cardiomyocyte 
adaptation to injury (Table 7). In a PH/RV failure model, chronic DHEA treatment over 5 
weeks in rats exposed to SuHx reduced RVSP and rescued CI and echocardiographic RV 
function (8). Treatment with DHEA inhibited capillary rarefaction, apoptosis, oxidative 
stress and NADPH levels, and fibrosis in the RV of these animals via reduced Rho kinase 
activity and inhibition of transcription factors implicated in maladaptive cardiac remodeling, 
STAT3 and NFATc3 (8). In rats exposed to chronic hypoxia followed by reoxygenation, 
DHEA increased RV myocyte density and proliferation, reduced mitochondrial 
fragmentation, and prevented RV dysfunction during the recovery phase of these 
experiments (88). These studies demonstrate that DHEA may have a direct and RV-specific 
effect independent of downstream hormones like E2.
Human Studies—Low circulating DHEA-S levels have been associated with an increased 
risk of death in heart disease, cardiac allograft vasculopathy, and heart failure severity (25, 
100, 155, 290, 373) (Table 2). In the MESA-RV study, higher levels of DHEA were 
associated with lower RVEF (calculated from RV stroke volume/RV end-diastolic volume), 
higher RV stroke volume (calculated from RV end-diastolic—RV end-systolic volume), and 
larger RV end-diastolic volume in postmenopausal women who did not have any clinical 
cardiovascular disease. While a lower RVEF and larger RV stroke volume seem difficult to 
reconcile, higher RV end-diastolic volume with higher DHEA levels would result in larger 
RV stroke volume and numerically but not pathologically lower RVEF given the derivation 
of these parameters. In fact, virtually all participants had a normal RVEF (these are “disease-
free” adults) in MESA and, as reviewed above, in postmenopausal women with PAH, lower 
DHEA-S levels were associated with worse RV dilatation and dysfunction by 
echocardiogram (444). The primary end point of the ongoing trial of DHEA 
supplementation in PAH is RV contractile function measured by cardiac MRI 
(NCT03648385).
In summary, the conglomerate of basic and clinical studies of DHEA in PH suggests 
beneficial effects on both pulmonary vascular and RV function (Tables 2 and 7).
Sex Hormone-Independent Effects
Sex steroid signaling clearly is a major driver of sex differences in susceptibility and disease 
progression in PH/PAH. However, the hormonal milieu is not the sole factor that impacts 
gender and sex-based differences in pulmonary vascular disease. Emerging research 
indicates that nonhormonal factors such as immune cell regulation, iron metabolism, and the 
Y chromosome itself may lead to sex-based differences in PH penetrance and progression.
A recent study demonstrated sexually dimorphic immune responses in experimental PH. In 
particular, the authors demonstrated that in regulatory T-cell (Tregs)-deficient rats exposed 
to sugen or hypoxia, females developed more severe PH than males (408). Interestingly, 
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Treg repletion abolished this sex difference. In additional studies, the authors showed that 
protective vascular effects of Tregs were ER dependent, suggesting a cross talk between the 
immune system and sex steroid signaling. This observation suggests that females are reliant 
on normal Treg function to counteract detrimental effects of pulmonary vascular insults. 
Patient registry data supports this hypothesis as PAH is often associated with autoimmune 
disorders, and many of these disorders share similar or more skewed gender ratios as in 
idiopathic PAH (27). This indicates that altered immune responses may contribute to the 
female predominance in PAH. How sex-based differences in immunity impact PAH, as well 
as the role of sex steroid signaling in immune cell regulation, remains to be investigated.
Iron deficiency is a common comorbidity with PAH in humans (344, 385). Since iron is a 
required for degradation of HIFs (prominent drivers of PAH development), iron deficiency 
may contribute to the development and progression of PAH in some patients (332). 
Intravenous iron supplementation is currently the focus of a phase II clinical trial in PAH 
patients (162). Both globally (266) and in the United States (119, 218), iron deficiency is 
two to three times more prevalent in women than in age-matched men, suggesting that 
women may be disproportionately vulnerable to iron deficiency-related HIF activation in the 
pulmonary vasculature. However, this hypothesis has yet to be tested.
Finally, recent research indicates that the Y chromosome itself may play a protective role in 
PAH progression. Umar et al. used the Four Core Genotype (FGC) mouse model, in which 
the chromosome complement is independent of gonadal sex, to demonstrate that the 
presence of the Y chromosome protects mice from HPH development regardless of sex 
(431). An explanatory mechanism for this phenomenon was proposed by Yan et al. who 
demonstrated that the Y-chromosome-encoded transcription factor SRY (sex-determining 
region of the Y chromosome) promotes Bmpr2 expression in cultured male dermal 
fibroblasts (477). Altered BMP signaling plays a major role in vascular dysfunction in 
PH/PAH (reviewed in Ref. 243), and germ line mutations in BMPR2 are found in most cases 
of heritable PAH (14), making the mechanism discovered by Yan et al. conceptually sound. 
Additional studies evaluating potential SRY-regulated Bmpr2 expression in the lung 
vasculature and in vivo would be of tremendous value to the field.
How to Put it all Together: Common Themes, Knowledge Gaps, and 
Pathways Forward
The aggregate of studies reviewed in this article demonstrates that there has been significant 
progress in the study of sex/gender differences and sex hormone signaling in PAH/PH. In a 
relatively short time span, the field has moved from mechanistic cell culture and animal 
studies to human studies including clinical trials of hormonal modulation, suggesting that 
harnessing sex hormone signaling may provide a powerful new strategy to treat PAH/PH. 
The observation that sex hormones interact with several major disease modifiers such as 
BMPR2 signaling, metabolic function, and RV adaptation indicates that sex hormone 
signaling is indeed a major disease modifier. The major biological effects of the most 
abundant sex hormones as well as their major effects in animal studies and their association 
with PAH outcomes in human studies are depicted in Figure 4. Several “themes” have 
Hester et al. Page 39













emerged: E2 has pleiotropic and compartment-specific effects, 16α-OHE1 promotes PAH 
development, and DHEA seems to be uniformly protective (Figure 4). E2’s RV-protective 
effects may explain why women with PAH have better RV function and live longer than their 
male counterparts. At the same time, E2 or its metabolites (in particular, 16α-OHE1) may 
promote pulmonary vascular remodeling and make certain women more prone to PAH 
development, especially in the context of additional predispositions, such as a BMPR2 
mutation. The roles of testosterone and progesterone, on the other hand, have not been well 
studied. Since sex hormones exert diverse and pleiotropic effects, and since sex/gender 
differences are mediated by multiple factors (Figure 5), further research is needed to identify 
context- and compartment-specific signaling pathways and sex-based phenotypes. 
Nonhormonal factors, such as Y-chromosome-mediated effects, aging, and immunity, have 
recently been identified and may affect disease development and/or progression. 
Consideration of these (as well as potential unidentified) factors and nuances will ultimately 
solve the “estrogen puzzle” of PAH. An overview of the major current knowledge gaps in 
the field is provided in Table 8. Given the pleiotropic effects of many sex hormones (and in 
particular, E2), it remains to be determined whether inhibiting or enhancing one specific 
hormone will be meritorious. Selectively targeting one receptor or one metabolite may be a 
more precise approach with less off-target effects. In addition, sex-based treatment strategies 
may depend on factors such as receptor expression, sex hormone abundance, ratios between 
various sex hormones, age, comorbidities, or specific genetic or epigenetic landscapes.
Summary and Conclusion
This article has comprehensively reviewed gender differences in human PAH and sex 
differences in animal studies as well as the physiology of sex steroid signaling in health and 
PAH. The role of nonhormonal contributors to sex and gender differences in PAH/PH is less 
well described, but these factors may play a significant role as well. Sex, gender, and sex 
hormones clearly are major disease modifiers in experimental PH as well as human PAH. 
Manipulation of sex steroid signaling pathways may open up several new treatment 
strategies. In addition, several sex-based phenotypes exist, suggesting that therapeutic 
strategies may need to be tailored toward such specific phenotypes. A better understanding 
of sex hormone signaling and sex steroid-independent factors will lead to novel and targeted 
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eNOS endothelial nitric oxide synthase
ESR1 estrogen receptor α gene
ESR2 estrogen receptor β gene
ET-1 endothelin-1
GPR30 G-protein-coupled receptor 30
HIF-1α hypoxia-inducible factor 1-alpha
HPAH hereditary pulmonary arterial hypertension
HPH hypoxia-induced pulmonary hypertension
HPV hypoxic pulmonary vasoconstriction
HT hormone therapy
IPAH idiopathic pulmonary arterial hypertension





PAB pulmonary artery banding
PAEC pulmonary artery endothelial cell
PAH pulmonary arterial hypertension (Group 1 PH)
PASMC pulmonary artery smooth muscle cell
PH pulmonary hypertension (all groups)
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PPT propylpyrazole triol (ERα agonist)
PR progesterone receptor
PVR pulmonary vascular resistance
RV right ventricle/right ventricular
RVEF right ventricular ejection faction
RVH right ventricular hypertrophy
RVSP right ventricular systolic pressure
SERT+ serotonin transporter overexpression
SMC smooth muscle cell
SNP single-nucleotide polymorphism
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• Pulmonary hypertension (PH) encompasses a heterogeneous group of 
diseases organized into five groups based on their predominant underlying 
pathology and clinical phenotype (Figure 1).
• The “estrogen puzzle” refers to two observations in PH research: (i) Many PH 
classes, particularly group 1 (PAH), are marked by sexually dimorphic disease 
presentation wherein women are at increased risk for disease development but 
display increased survival compared with men and (ii) animal models 
demonstrate contradictory effects of estrogen signaling in PH disease 
progression (protective as well as detrimental).
• Human and animal studies have shown varied effects of 17β estradiol (E2) in 
the pulmonary vasculature in PAH/PH, but consistently show that E2 
promotes healthy RV function and adaptation. Disease-promoting effects of 
E2 in the pulmonary vasculature are mediated at least in part by pro-
proliferative metabolites (e.g., 16α-hydroxyestrone).
• Few studies have examined the effect of progesterone or androgen signaling 
in PH though these hormones possibly play a role in disease susceptibility and 
progression.
• DHEA is protective in animal models of PH, and circulating DHEA levels in 
PAH patients correspond positively with PH endpoints and RV function in 
humans.
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Figure 1. Current classification of pulmonary hypertension (PH) and subtypes with evidence for 
sexually dimorphic features.
PH classification from 6th World Symposium (Nice, 2018) according to Simonneau et al. 
(351). In addition to the data presented here, one study in a large cohort of veterans with all 
types of PH (predominantly Group 2 and 3 PH; n = 15,464 patients) demonstrated that 
women with PH exhibit higher pulmonary vascular resistance and pulmonary artery pulse 
pressure, yet lower RAP as well as 18% greater survival compared to men with PH. *These 
analyses predominantly included patients with idiopathic PAH and also patients with 
heritable PAH and drug- and toxin-associated PAH (no subgroup analyses performed). 
#Attenuated hypoxia-induced PH in women not consistently found across studies. BMPR2, 
gene encoding bone morphogenic protein receptor 2; CYP1B1, gene encoding cytochrome 
P450 1B1; CYP19A1, gene encoding aromatase; ESR1, gene encoding estrogen receptor α; 
HFpEF, heart failure with preserved ejection fraction; HIV, human immunodeficiency virus; 
HT, hormone therapy; LVEF, left ventricular ejection fraction; PCH, pulmonary capillary 
hemangiomatosis; PVOD, pulmonary veno-occlusive disease; PVR, pulmonary vascular 
resistance; RV, right ventricle; SNP, single-nucleotide polymorphism; SSc, systemic 
sclerosis.
Hester et al. Page 74













Figure 2. Pathophysiology of PAH.
(A) Arterial cross section illustrating PAH pathology in the pulmonary arteries. Proliferation 
of endothelial cells (ECs), smooth muscle cells (SMCs), and fibroblasts leads to vascular 
remodeling with eventual occlusion of diseased vessels. Neoangiogenesis driven by 
apoptosis-resistant proliferative ECs, SMCs, and other resident PA and recruited cells 
promotes formation of plexiform vascular lesions, which are the hallmark of PAH. Plexiform 
lesions may be seen within pulmonary vessels as well as extending into the adventitial tissue 
(not shown). Infiltration of PH vascular lesions by immune cells and bone marrow-derived 
cells drives a pro-inflammatory and pro-proliferative state in the tissue. (B) Transverse 
section of the heart. High pulmonary vascular resistance in PAH produces increased 
afterload on the RV, resulting in adaptation and RV failure in PAH. RV hypertrophy may be 
adaptive and compensatory to overcome PVR and maintain cardiac output (not shown). On 
the other hand, RV hypertrophy may be maladaptive, marked by vessel rarefaction, 
metabolic dysfunction, inflammation, cell death, fibrosis, and increased RV dilatation. 
Maladaptive RV remodeling is associated with RV ischemia and decreased RV ejection 
fraction and cardiac output, resulting in RV failure.
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Figure 3. Sex hormone synthesis and estrogen metabolism.
Steroidogenic enzymes represented here are present in the lung, heart, and/or vascular tissue 
(148, 197, 314, 317, 480). Abundance of boxed enzymes is altered in PH/PAH (12, 326, 340, 
457, 462-464). Compounds in red have been targeted in clinical trials of PAH therapies 
(193). 2-Hydroxyestradiol and 2-methoxyestradiol exert ER-independent antiproliferative, 
anti-inflammatory effects that appear to mitigate vascular remodeling in animal models of 
PAH (22, 82, 421). Conversely, the estrogen metabolites 4-hydroxyestradiol, 4-
methoxyestradiol, and 16α-hydroxyestrone signal via estrogen receptors and promote a 
mitogenic, inflammatory, and antiapoptotic phenotype that exacerbates PH/PAH (54, 463). 
*Multiple CYP enzymes are capable of catalyzing estrogen hydroxylation; CYP1A1 and 
CYP1B1 appear to be the most relevant isoforms in PAH pathology. Factors including diet 
(240, 275), hypoxia (107), inflammation (11), genetics (12, 146), and drug exposure (71) 
may alter estrogen metabolism. Effects of enzymes and metabolites depicted here may be 
cell-, tissue-, and/or organ specific.
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Figure 4. Overview of major biological effects of the most abundant sex hormones (A) and their 
net effects in animal studies as well as reported associations with PAH risk and outcomes in 
human studies (B).
Note that effects of specific sex hormones on outcomes in human studies may be limited to 
men or pre- or postmenopausal women only. Human studies measured DHEA-S 
(dehydroepiandrosterone sulfate). *Data based on study only. #Inconsistent associations 
across studies. DHEA, dehydroepiandrosterone; PA, pulmonary artery; PAEC, pulmonary 
artery endothelial cell; PAH, pulmonary arterial hypertension (human studies); PASMCs, 
pulmonary artery smooth muscle cells; PH, pulmonary hypertension; RV, right ventricle.
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Figure 5. Simplified overview of factors contributing to sex/gender differences and sexual 
dimorphism in PAH and PH.
Note that significant cross talk exists between the factors and mediators listed in this figure. 
BMPR2, gene encoding bone morphogenic protein receptor 2; CYP1B1, gene encoding 
cytochrome P450 1B1; CYP19A1, gene encoding aromatase; DHEA, 
dehydroepiandrosterone; ESR1, gene encoding estrogen receptor α; SNP, single-nucleotide 
polymorphism.
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